Genomics and Epigenomics of Common Human Metabolic and Heart Disease by Multhaup, Michael Lewis
 
 




Michael Lewis Multhaup 
 
 
A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree 










The field of epigenetics is rapidly becoming recognized as playing an essential part in explaining common 
human disease. Here we probe DNA methylation in diabetes mellitus and associated metabolic 
phenotypes and coronary heart disease. In a cohort from the Framingham Heart Study, we use 
epidemiological techniques to identify over 20,000 CpGs differentially methylated in coronary heart 
disease patients. In the other chapters, we use a functional approach to investigate the epigenetics of 
Type 2 Diabetes (T2D) and combine three lines of evidence – diet-induced epigenetic dysregulation in 
mouse, epigenetic conservation in humans, and evidence of T2D clinical risk – to identify genes 
implicated in T2D pathogenesis through epigenetic mechanisms related to obesity. We then replicate 
these results in adipose samples from lean and obese patients pre- and post-Roux-en-Y gastric bypass 
surgery, identifying regions where both the location and direction of methylation change is conserved. 
These regions overlap with 27 genomic locations with genetic T2D risk, only one of which was deemed 
significant by GWAS alone. Functional analysis of genes associated with these regions revealed five 
genes with novel roles in insulin resistance, demonstrating the potential general utility of this approach 
for complementing conventional human genetic studies by integrating cross-species epigenomics and 
clinical genetic risk. 
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The history and current status of epigenetics 
 
 Epigenetics is typically defined as maintenance or reproduction of information through cellular 
division that occurs without changes in the primary DNA sequence. Originally coined by Conrad 
Waddington in 1942, the term “epigenetics” was originally used to mean the forces that shaped 
genotype into phenotype according to his “canalization” theory where the almost infinite potential 
chaos of the human genome was channeled into a much smaller number of recognizable phenotypes 
(Waddington, 1942). Many years later, Robin Holliday, contemplating his studies of drosophila 
development, more narrowly defined epigenetics as the manner in which the properties of genes 
change “during the development of the organism from fertilized egg to adult” (Holliday, 1987) and later 
as “the study of changes in gene expression, which occur in organisms with differentiated cells, and the 
mitotic  inheritance of given patterns of gene expression” (Holliday, 1994). In this same paper, Holliday 
proposes a subcategory of epigenetics as a transmission of information “other than the DNA sequence 
itself.” This subcategory definition quickly gained traction, presumably because of its useful contrast to 
genetic inheritance, and has become common parlance today. 
 Quite a few biological mechanisms could fit within the umbrella of this definition. One could 
postulate that the anterior-posterior axis positioning in embryo development is epigenetic, as the 
positioning information (not genetic) gives rise to changes in gene expression that last the lifetime of the 
cells. Similarly, certain types of stem cell polarity arise from the local cellular environment (not genetic) 
and give rise to differential gene regulation patterns in daughter cells that are then passed on. In 
practice, however, the term “epigenetics” is most commonly used to refer to two systems: DNA 
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methylation (the covalent modification of DNA bases) and histone modification (the post-translational 
modifications of histone molecules or their substitution) (Dupont et al., 2009). 
 The covalent modification of DNA bases was first described in 1948, when a study attempting to 
perfect a method of using paper chromatography to separate out the five nucleotides found extra 
spectrophotomer absorption peaks, including one near cytosine that they termed “epicytosine” 
(Hotchkiss, 1948). Later, DNA modification was first postulated to have the potential to affect gene 
expression in a 1969 opinion piece that attempted to create a plausible explanation for the persistence 
of human memory and proposed long-term (covalent) modification of DNA in neurons leading to the 
alteration of gene expression within neurons – the “DNA ticketing theory of memory” (Griffith and 
Mahler, 1969). While this theory of human memory turned out to be incorrect, its mechanism may not 
have been too far afield; recent studies have found an enrichment of hydroxymethylation (5-
hydroxymethylcytosine; 5-hmc) within certain areas of the brain (Wang et al., 2012). 
 In vertebrates, DNA methylation most commonly occurs at the cytosine in a cytosine-guanine 
dinucleotide (CG), though it has been found to occur infrequently in a few particular cell types on the 
cytosines in cytosine-alanine and cytosine-thymine sequences as well (Ramsahoye et al., 2000). This 
methylation occurs at the 5 position of the cytosine ring, counting towards the carboxyl group from the 
nitrogen between the amine and carboxyl groups. S-adenosylmethionine (SAM-CH3) donates the methyl 
group, which then replaces the 5’-hydrogen atom to form 5-methylcytosine in a reaction catalyzed by a 
group of enzymes known as DNA methyltransferases (DNMTs).  
 There are three main DNMTs in mammals – DNMT1, DNMT3a and DNMT3b. All of these genes 
are essential, and full knockouts of these genes inevitably lead to mortality (though DNMT3a -/- mice 
can live to up to four weeks of age) (Okano et al., 1999). A fourth enzyme, DNMT2, was named for its 
close homology to DNMT1 but does not actually possess any DNA methyltransferase activity. It was 
recently revealed to actually be an RNA methyltransferase, responsible for the methylation of aspartic 
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acid transfer tRNA (Goll et al., 2006). All DNMTs have the same basic mechanism (Bestor, 2000). First, 
sequence recognition domains in the various enzymes make contact with bases in the major groove of 
the DNA double helix. Second, the target cytosine is removed from its usual base-pairing and inserted 
deep within the enzyme itself. Third, the enzyme makes a temporary covalent bond at the cytosine 4 
position to create a more reactive 5 position. Fourth, the newly reactive 5 position strips a methyl group 
from S-adenosyl-methionine (SAM), the methyl donor. Fifth, the enzyme reforms the double bond 
between the 4 and 5 positions, releasing itself from the cytosine. 
 While all three DNMTs use this mechanism, their functions are very different. DNMT1 is the 
“maintenance” enzyme, responsible for the perpetuation of methylated cytosines through DNA 
replication and cell division. In DNA replication, newly synthesized DNA is created from unmethylated 
cytosines and therefore has no methylation. However, the semi-conservative nature of DNA replication 
means that every new strand of DNA will pair with a previously existing, methylated strand. This creates 
what is known as “hemi-methylated” DNA, where the methylated CGs on the parental strand are paired 
with unmethylated CGs on the daughter strand. DNMT1 specifically recognizes these hemi-methylated 
sites, binds to them, and methylates the unmethylated CG on the daughter strand. This leads to the 
theoretically perfect copying of methylation position information through cell division. 
 DNMT3a and 3b are known as the “de novo” methyltransferases, as they have an equal 
preference for unmethylated and hemi-methylated DNA (Okano et al., 1998). They are thought to be 
responsible for the placement of new methylation marks during development and when one cell type 
turns into another, as in hematopoiesis (Challen et al., 2014). The mechanism by which these 
methyltransferases are targeted to specific areas of the genome, however, is not yet fully understood. It 
is known that DNMTs can be attracted and/or activated by specific histone modifications (Li et al., 2011), 
raising the possibility that the histone code landscape could influence the DNA methylome. DNA 
methylation is also known to influence histone marks at specific genomic loci (Cedar and Bergman, 
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2009), which could potentially lead to a chicken-and-egg problem. Many biological systems, however, do 
not have perfectly defined start and end points, and are simply feedback loops that continually self-
regulate, as may be the case here. 
 Lastly, DNA methyltransferase 3-like (DNMT3l), while not a DNA methyltransferase itself, has 
strong homology to the DNMT3 family (Aapola et al., 2000). Initial characterization of DNMT3l has found 
that it can bind physically to DNMT3a and 3b (Okano et al., 1998), stimulate DNMT3a activity (Chedin et 
al., 2002), and help localize histone deacetylases (HDACs) (Aapola et al., 2002) . 
DNA methylation in general causes a problem for DNA repair machinery, in that a particular kind 
of DNA damage - spontaneous deamination - causes methylcytosine to change into thymine. As thymine 
is another standard DNA base, there is no obvious fault for the DNA repair machinery to correct. By 
contrast, the spontaneous deamination of unmethylated cytosine creates uracil. As uracil is not normally 
a base found within DNA, repair enzymes can identify and remove it. While the rate of spontaneous 
deamination is fairly low (Shen et al., 1994), over the eons that CG methylation has been utilized by 
vertebrate evolution this undetectable change from C to T has led to an imbalance of CGs in the 
genome, with CGs representing only 1% of dinucleotides in the genome compared to > 4% frequency for 
all other dinucleotides pairs. Methylation is very prevalent among these remaining CGs, with > 70% of all 
CGs methylated in humans (Ziller et al., 2013). 
 This methylation is not evenly distributed, and neither are the underlying CGs. Studies 
examining CG density and methylation across the entire human genome have found that many CGs are 
found clustered together in what are known as “CpG islands.” Many of these clusters are found in 
transposon repetitive elements, and are at least as highly methylated as the rest of the genome. The 
remainder (~40,000 out of ~350,000 total, depending on the exact definition used) are in the non-
repetitive genome, are generally un-methylated, and often (~50%) overlap with transcription start sites 
(TSS) and gene promoters (Glass et al., 2007). The remaining 50% that do not overlap with TSSs are at 
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genomic locations often display signs of transcription (Maunakea et al., 2010), making this genomic 
feature a very common de facto promoter element.  
This relationship (un-methylated CpG islands at the promoters of genes) has given rise to the 
classical inverse relationship between DNA methylation and gene expression, where lower “levels” of 
DNA methylation in a particular genomic region are associated with increased gene expression. There 
are two main biological mechanisms for this association. The first is a direct interference of the ability of 
many transcriptional activators to bind to methylated DNA, usually through steric interference; the 
second is the ability of methylated DNA to recruit inhibitory factors (often through the mediation of 
methyl-binding protein 1 and 2 (MeCP1 and MeCP2) that in turn will interact with other proteins to 
spread inhibitory histone marks and a condensed chromatin structure (Tate and Bird, 1993). These 
mechanisms and inverse association, however, are not as straightforward outside CpG islands. 
The several thousand bases outside these CpG islands have in recent years become known as 
“CpG island shores” or “CG shores.” These regions are also relevant epigenetically, as most DNA 
methylation differences between tissues are found in shores (Irizarry et al., 2009). The relationship of 
methylation to gene expression in these regions is much more complicated than within CpG islands and 
appears to depend on the precise location of methylation within the genome and the identity and 
function of other factors binding in that region. In addition to its classical role in regulating expression 
and promoter CpG islands, methylation is known to promote and repress alternate transcription start 
sites (Maunakea et al., 2010), affect mRNA splicing (Oberdoerffer, 2012), modulate splicing sites within 
genes (Maunakea et al., 2013), positively affect gene expression when within gene bodies (Yang et al., 
2014), and promote gene expression when at repressor binding sites (Ando et al., 2000). Generally, the 
biological mechanisms for these processes appear to be the same – direct interference with TF binding 
or the creation of binding sites for proteins like the MeCPs. The difference appears lies in location; it is 
easy to see how interference with the binding of an expression-promoting factor at a gene promoter will 
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have opposite effects as interference with the binding of a transcriptional repressor at an upstream 
enhancer element. 
Within the cell’s nucleus, DNA is not simply a tangled bundle of double helix spaghetti. DNA is 
almost all wound and packaged around proteins known as histone complexes. Each histone complex 
consists of eight subunits: two each of the histone proteins H2A, H2B, H3 and H4. The unit of a histone 
complex and the approximately 147 bases of DNA wrapped around it is called a nucleosome, and these 
nucleosomes comprise the fundamental unit of chromatin – a term for the overall organization of DNA 
and associated macromolecules within a cell. The most obvious purpose of this wrapping is packing. If 
strung out, the DNA in each human cell would be almost five feet long. Wrapped around histones, 
however, the nucleosomes only stretch out 90 micrometers (Redon et al., 2002). 
Histones, however, are not merely spools around which DNA is wound. The H3 and H4 subunits 
have “tails” that protrude, and these tails can greatly influence the types of proteins that bind to DNA. 
An enormous variety of post-translational covalent modifications occur on these tails, creating a diverse 
mosaic of possible binding sites for other proteins. Taken together, the sum of these post-translational 
modifications are known as the “histone code” and comprise at least six different types of post-
translational modifications occurring at different amino acids along the H3 and H4 tails. As each 
combination of different histone marks at different places potentially comprises a binding site for a 
different protein, the histone code has been postulated to be a cellular “language” with a vocabulary 
consisting of thousands to millions of words. 
A full review of every histone modification and position is beyond the scope of this work, but 
one example will be presented here. Histone acetylation has been observed to occur on at least five 
different lysines on the H3 tail and four lysines on the H4 tail (Cell_Signaling_Technology, 2014). These 
marks are placed by a class of enzymes known as histone acetyltransferases (HATs), of which there are 
at least five different families, and removed by enzymes known as histone deacetylases (HDACs), of 
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which there are at least four major types. Normally, lysines have a positive charge. Histone molecules 
are fairly lysine rich, and it is thought that the interaction of the negatively charged DNA and the 
positively charged lysines helps stabilize the interactions between histones and DNA. Lysine acetylation, 
however, eliminates the positive charge of the lysine, leading to decreased interaction between DNA 
and histone, and ultimately in DNA that is less tightly bound. This has the effect of making the DNA more 
accessible to transcription factors and transcription machinery, allowing more gene expression. In 
addition to this physical effect, however, many transcription activating proteins have bromodomains 
that bind directly to acetylated lysines on the histone tails, bringing them into close contact with the 
DNA. The end result of this acetylation is a strong correlation between histone acetylation and gene 
expression, especially at gene promoters. 
Epigenetics, however, is not merely the modulation of gene expression; it is also the 
perpetuation of these modulations through cell division. Unlike DNA methylation and the DNMT1 
enzyme that provides a clear and easy mechanism for its perpetuation through DNA replication, no 
certain mechanism of histone code cellular memory is known. Without such a mechanism, any changes 
that occur to histone marks must necessarily be transient and would probably not make a lasting 
difference to the organism. This is somewhat difficult to square with the known specificity of histone 
modifications. Histone acetylation, for example, does not occur randomly throughout the genome, but 
instead occurs specifically at active genes, and at the same active genes in daughter cells. Is there a 
system to simply place histone marks anew in the correct places at the end of every cell division? Or are 
there systems in which the actual location of histone marks are copied over onto newly synthesized DNA 
through mitosis? 
Recently, several theories have been proposed as to a mechanism for histone code cellular 
memory. As an example, EZH2 is the enzyme that causes tri-methylation at lysine 27 on H3. It has been 
observed that EZH2 not only methylates this lysine, but continues to co-localize with this mark even 
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during DNA replication (Hansen et al., 2008). It has therefore been proposed that this close association 
with H3K27me3 domains could allow the methylation of the newly synthesized DNA almost as soon as it 
is made, essentially copying the information from the old strand to the new. If true, this would represent 
a form of memory through cell division that would elevate at least one histone mark to full epigenetic 
status. 
Thus far, only the normal functioning of epigenetics has been reviewed – what happens if these 
systems become disrupted? Because of the persistence of epigenetic marks, disruptions and deleterious 
changes could be maintained by cells and their descendants, slowly spreading throughout the organism, 
much like a genetic mutation. Unlike a genetic mutation, however, epigenetic disruptions could be 
acquired long after birth by anyone, regardless of the genotypes of their parents. Indeed, a growing 
body of literature, including work discussed in the later chapters of this thesis, show that deleterious 
disruptions in the systems of epigenetic mark placement and maintenance (epi-mutations) can be found 
in many long-lasting conditions and diseases and can be initiated by common environmental factors 
affecting everyone. 
The first major human disease found to be systematically associated with wide-spread 
epigenetic changes was cancer (Feinberg and Vogelstein, 1983). Exact patterns of differential 
methylation in cancers have been shown to be idiosyncratic both for different types of cancers and even 
for different individual tumors of the same cancer type. Despite this, however, there are several overall 
patterns observed in the majority of cancers – large-scale loss of DNA methylation (hypomethylation) 
and region-specific gain of DNA methylation (hypermethylation). As an example, a recent study of colon 
cancer found many differentially methylated regions (DMRs), with most of the hypermethylation taking 
place near CpG islands, and most of the hypomethylation taking place further away, at the CpG island 
shores that normally have colon-specific methylation patterns (Irizarry et al., 2009). 
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Interestingly, despite large epigenetic changes taking place in nearly all examined cancer types, 
it has been difficult to come up with easily usable DNA methylation biomarkers for cancer. This appears 
to be due to the overall variability of individual marks – while there are changes taking place in most 
cancers, the odds of any individual CG being differentially methylated in a specific tumor is less than 
definitive. This variability, however, may be in itself a biomarker. Recent work examining specific genetic 
regions in cancer versus normal samples has found that while most regions feature some individual 
tumors having the same methylation levels as normal tissue, rendering them difficult to use as a 
biomarker, the examination of multiple regions across the genome allowed tumor samples to be 
identified as having overall increased methylation variability (Hansen et al., 2011). This increase in 
variability even appeared to progress with tumor metastasis, making the measurement of methylation 
variability a potential assay for the future metastasis potential of apparently benign tumors. The general 
biological hypothesis explaining how increased epigenetic variability in itself could lead to more 
pathogenic tumors is based in selection  (Ohlsson et al., 2003). While not all cells will have epigenetic 
changes that promote the unrestricted growth common in cancer (increased expression of growth 
genes, decreased expression of apoptotic or tumor-suppressor genes), in a large population of cells, 
statistically at least a portion of the cell population will have these types of changes, and these cells will 
begin to propagate without restraint. 
Dysregulated epigenomes are not limited to cancer, however. Theoretically, epigenetic changes 
provides an excellent candidate mechanism for any disease that is persistent but not genetically 
determinative. In the last decade, investigators have found epigenetic changes in a wide of range of 
different diseases and conditions. Aside from cancer, epigenetic changes have been associated with 
systemic lupus erythematosus (Javierre et al., 2010), autism (Nguyen et al., 2010), Type 1 Diabetes 
(Rakyan et al., 2011), Type 2 Diabetes (T2D) (Volkmar et al., 2012) (Multhaup et al., 2015), coronary 
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heart disease (CHD) (Sharma et al., 2014), rheumatoid arthritis (Liu et al., 2013b),and bacterial 
inflammatory responses (Shuto et al., 2006). 
Interestingly, many of these diseases are known to have a genetic component as well. Both T2D 
and CHD have over 50 individual genetic single nucleotide polymorphisms (SNPs) associated with risk for 
these diseases (Welter et al., 2014). In both these diseases, the cumulative effect of these SNPs can only 
explain less than 20% of the disease risk, and the genetic basis of these diseases as a whole can only 
explain ~50% of disease risk (more detail on these two diseases in Chapters 2 and 4 of this work). This 
makes sense, as environmental factors, such as diet for T2D and smoking for CHD, are known to play 
huge roles in the development of these conditions (Kannel et al., 1987). 
Epigenetics is known to be influenced by both the environment and by the genetic landscape. 
Recent studies have shown large epigenetic changes between genetically identical animals that have 
received different diets (Multhaup et al., 2015). On the genetic side, work on blood from rheumatoid 
arthritis patients have shown that particular SNPs are tightly associated with the methylation status of 
individual CpGs (Liu et al., 2013b), implying that the genetic makeup of an individual can also affect the 
epigenome. Together, these two findings show the potential for epigenetics to actually mediate 
between the genetic and environmental bases of many common human diseases, a potential that has 
been invoked as a hypothesis for the basis behind the post-childhood onsets and progressive nature of 
many common human diseases (Bjornsson et al., 2004). 
The methods used in the study of epigenetics have evolved over the years. The original methods 
were chromatography based and could only be used on bulk DNA (Hotchkiss, 1948). DNA methylation 
analysis was transformed with the advent of two technologies – bisulfite treatment and sequencing. The 
chemical bisulfite (hydrogen sulfite), when added to DNA, will convert all cytosines into uracil by 
bringing about deamination as discussed above. After amplification, usually with polymerase chain 
reaction (PCR), these uracils are replaced with thymines, resulting in the conversion of all C nucleotides 
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into T. Methylated DNA, however, is protected from this process. The combination of bisulfite and PCR 
allows the measurement of methylation (by examining the placement of the only remaining Cs in the 
genome) after amplification. This measurement is usually accomplished via sequencing. Originally, 
Sanger sequencing was used to measure DNA methylation in a technique called cloning bisulfite 
sequencing (Zhang et al., 2009). In this method, DNA was extracted from a sample of interest, bisulfite 
treated, and then the genomic location of interest was PCR-amplified. These sequences were then 
cloned into bacteria such that bacterial colonies represented individual DNA strands from the original 
sample. The sequencing of a sufficient number of these bacterial colonies would then give information 
on the same number of individual strands from the original sample, thus allowing quantification of DNA 
methylation. 
This approach had a number of drawbacks, however, especially involving the effort and 
intermediate step of moving through bacteria and also the inability to examine more than a few regions 
at a time. The problem with having to use bacteria as an intermediary step, however, was solved with 
the creation of the bisulfite pyrosequencing method (Tost and Gut, 2007). In this method, DNA is 
extracted from the sample of interest, bisulfite-treated, PCR-amplified, and then sequenced directly by 
pyrosequencing. Pyrosequencing is a method in which SNPs can be quantified with a high degree of 
precision (within 5%) via light released by a reaction involving a series of enzymes during DNA 
polymerase procession over the site of interest. The increased specificity in determining SNPs allows the 
quantification of the percent cytosine at a particular genomic location, and thus the quantification of the 
amount of DNA methylation originally at that location. 
The lack of throughput associated with only being able to examine a specific area of the genome 
were ameliorated with microarray technology. Briefly, microarrays used to examine DNA have millions 
of single-stranded DNA fragments attached with microscopic precision to a small slide. When sample 
DNA is made single stranded and allowed to wash over this slide, it will bond to corresponding DNA 
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fragments on the microarray if present. The amount of DNA bound to the slide (corresponding to the 
amount of DNA in the actual sample) can then by quantified via the attachment of fluorescent dyes to 
the ends of these fragments and then by taking an incredibly high-resolution picture of the resulting 
pattern of light. With the knowledge of the original location on the slide of the attached DNA, the 
amount of light corresponding to each original DNA fragment can then be assigned (by computers) to a 
unique position within the genome, allowing quantification of the amount of DNA from that position 
that was in the sample. 
This technology was paired with chromatin immunoprecipitation (ChIP) and DNA 
immunoprecipitation (DIP) to examine DNA methylation and histone marks genome-wide. In these 
techniques, antibodies against either specific histone marks or DNA methylation are used to create 
samples enriched for the antibody ligand. These enriched samples are then paired with non-enriched 
samples, and labeled with different fluorescent dyes on the microarray. By comparing the amount of the 
dyes at a particular spot on the microarray, the relative enrichment of the immunoprecipitated mark of 
interest at the corresponding genomic location (and all genomic locations on the array) can be 
ascertained. Other methods can also be used to create enriched samples for microarraying as well. For 
instance, one method used in this thesis, comprehensive high-throughput array-based relative 
methylation (CHARM), uses an enzyme pair known as McrBC that cuts DNA only at methylated cytosines 
(Irizarry et al., 2008). Putting two differentially labeled samples on the microarray – an untreated sample 
and a DNA sample cut with McrBC – allows the quantification of relative amounts of DNA methylation at 
specific genomic loci. 
While originally small, containing only several thousand DNA segments, microarrays are now 
very complex, with the popular Illumina Infinium BeadChip 450k array being able to measure more than 
450,000 individual sites. Other, more expensive arrays, such as the latest version of CHARM, can 
13 
 
measure millions of individual genomic sites (Multhaup et al., 2015). This method of genome-wide 
epigenetic measurement, however, is rapidly being superseded by next-generation sequencing. 
Next-generation sequencing is a term for a small collection of different technologies that can 
sequence large amounts of DNA very quickly and relatively cheaply. In bisulfite sequencing, DNA from a 
sample is bisulfite treated, “libraries” are created from it (the DNA is fragmented and modified with 
special ends), and then fed directly into the next-generation sequencing machine. One example, the 
Illumina Hiseq, then uses a method called sequencing by synthesis to determine the makeup of the DNA 
sample. In this method, single-stranded fragments of DNA are equipped with a primer, and then the 
corresponding strand is synthesized. The synthesis is done with fluorescently tagged nucleotides, with 
the fluorescent specific for each nucleotide. After each nucleotide is added, a laser excites the tag such 
that it produces light, allowing the determination of exactly which of the four nucleotides attached to 
the DNA. As next generation systems are capable of probing millions of sites at the same time and 
rapidly progressing through the synthesis reactions, this will result in obtaining data on huge swathes of 
the genome, more than allowable with microarray technologies. While the cost of this technique is still 
higher than microarrays, it is rapidly decreasing, and within a few years next-generation sequencing will 
become the standard. 
Once data is generated by any method, it must be analyzed, and large datasets present their 
own analysis problems. The scientific community has responded with a large variety of analytic 
solutions, some of which are used in this thesis and will be discussed here. 
The first problem facing analysis is normalization. Most of the methods discussed above involve 
comparing the amounts of multi-colored light. This has to be translated into numbers suitable for 
analysis. This is not a simple procedure. As an example, consider readouts from two probes from the 
CHARM array discussed above. One probe has half as much light associated with the methyl-depleted 
sample as the other, and 75% as much light associated with the untreated sample. How much more 
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methylation does the first sample have? Please also consider that different sequences in the underlying 
DNA will have effects on the intensity of signal (Aryee et al., 2011).  
In this work, this problem is solved through the use of subset-quantile normalization both for 
CHARM (Aryee et al., 2011) and for analysis of Illumina Infinium 450k BeadChip arrays (Aryee et al., 
2014). This method takes control probes – probes designed specifically to have no methylation – and 
uses these as “anchors” to create a known bottom for the curve of methylation values. The values for 
the other probes on the array are then matched to a methylation curve anchored by these control 
probes and scaled such that the probes with the highest values represent 100% methylation. This is 
done within each individual sample. This procedure is also carried out between samples, with 
corresponding control probes being matched across samples to normalize distributions and then 
quantile normalization occurring, with the distributions of non-control probes being matched to the 
corresponding probes on the other samples. 
Once normalization is completed, the data now represents a set of reliable values. Each sample, 
however, may not be as reliable. Quality control (QC) is needed to identify samples that may have less 
high-quality data than the others. There are many reasons for technical sample failure. Individual 
samples may come from higher- or lower-quality DNA, and this can be reflected in the final data. 
Samples can be switched during processing and this is unfortunately common in studies with large 
numbers of samples (Lynch et al., 2012). Errors can be made during the processing of individual samples, 
causing them to fail to amplify as well as others or to hybridize to the DNA fragments on the microarray. 
All of these effects must be looked for and affected samples removed. Most of the techniques used to 
identify these samples are the same as used to look for batch effects. 
In addition to potential severe problems with individual samples, studies with large numbers of 
samples can suffer from issues that can affect large numbers of samples in more subtle ways – “batch 
effects.” These are issues that will generally affect groups of related samples and cause the measured 
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methylation values to be not noticeably wrong, but certainly different from other groups of samples, 
potentially affecting any comparison that involves samples from each group. Generally batch effects will 
arise between samples that were processed at different times, but the source of these effects can be 
due to a variety of factors. Protocols can be done slightly differently on different occasions, often in 
innocent ways – possibly slightly longer washes or sample thawing times – and these can have small but 
noticeable effects. Large microarray batches have been attributed to different technicians following the 
same protocol (Leek et al., 2010). Time of day or year that the samples were processed can create 
batches, possibly due to different amounts of ambient ozone in the atmosphere slightly changing the 
fluorescence chemistry (Fare et al., 2003). The list of specific causes is nearly endless, and many simply 
cannot be fully controlled for. 
Luckily, however, there are methods to identify and compensate for batch effects. The first 
method that should always be employed, even before starting the experiment, is stratification. If the 
experimental question being asked – e.g., comparing fat to lean mice – is completely confounded with a 
batch effect – e.g., all fat mice are in one batch and all lean mice in another – then there will be no way 
to separate out the effects of the scientific question and the batch. Therefore, samples from different 
experimental groups should be separated out – stratified – across foreseeable batches. For microarray 
experiments, this means separating out case and control samples across different plates of samples and 
different days of sample processing. In contrast, if there are individual samples that are tightly linked – 
e.g., samples that are paired across a timepoint – then these samples should be processed together in 
order to reduce variability. 
Once an experiment is performed, the first thing that should be examined is the absolute 
intensity of the results from each samples. Samples that fail dramatically often have vastly lower 
intensities than successful samples, can easily be identified by looking for outliers in intensity plots, and 
should be discarded. Second, the overall curve of results from each sample should be examined. In 
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general, these are called density plots. DNA methylation in most tissues has bimodal overall values, with 
most DNA methylation being around 10% or 90%. If a sample, or group of samples, has a hugely 
different overall methylation landscape, this is also often an indication that a technical artifact has 
affected that sample. At this stage, however, groups of samples affected in the same way should be 
checked for their relation to the experimental phenotype before being removed. DNA methylation on 
the X and Y chromosomes can be used to identify sample sex with high accuracy. If this predicted sex 
does not match the annotated sex, this can be a strong indication that a sample swap has occurred, and 
these samples should be removed unless the sample swap can be reverse-engineered and the correct 
annotation assigned. 
Principal component analysis (or surrogate variable analysis – almost identical mathematical 
operations) deserves a special mention as the best way to identify subtle batch effects. In these 
operations, dimensions of the greatest variability in the data are progressively extracted without regard 
to the original dimensionality of the data. In practice, each principal component is a number given to 
each sample. There are a number of principal components equal to the original dimensions of the data – 
e.g., for a data set consisting of only two dimensions (a plot of height versus weight), there will be two 
principal components. These principal components are ranked, such that the first principal component 
represents the largest single dimension of variability in the data. While these principal components do 
not correspond 1:1 with any of the original datapoints, they are often informative in and of themselves, 
and can usually be plotted against the original data dimensions to understand the causes of the 
variability they represent. As an example, consider the first principal component for a hundred samples 
of methylation data from fat and lean mice. Each of these samples has a number representing its 
contribution to the first principal component. These numbers are not evenly distributed, however. Half 
the samples have numbers around 1, and the other half around 2. Examining these samples, this binary 
distribution does not correspond to the fat or lean samples of the mice. After examining the association 
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of several other variables, however, it is observed that this binary distribution corresponds very well 
with the two different groups in which these samples were processed prior to microarray hybridization. 
This means that the source of the greatest variability within this dataset is not due to the primary 
scientific question of the mice being either fat or lean, but instead is due to a technical artifact. This 
situation is very common in microarray analyses and necessitates that this batch be dealt with before 
any comparison between experimental groups. 
Once principal components are identified, what can be done about them? One possibility is that 
they can be removed from the data. Using either linear regression or more complicated Bayesian 
methods such as ComBat (Johnson et al., 2007), the effects of these batches on the data itself can be 
predicted and removed. This is not a perfect guarantee of removal, as these methods assume linearity of 
effects; if the batch has a non-linear effect on the data, or interaction effects with other phenotypes or 
batches, these will not be removed. 
A second possibility for dealing with batch effects involves building them into the linear 
regression model used to predict the effects of covariates on the phenotype of interest. In general, 
linear regression is the most widely used method for examining the effect of one variable on another. In 
the context of microarray experiments, one linear model is created for each probe on the array, and this 
model will represent how well methylation at that probe predicts the phenotype of interest. These 
models can become very complicated, however, as variables other than methylation will contribute to 
the phenotype as well, and these should also be accounted for in the model. The most common 
examples include age, sex, and gender. If these are not included in the model, then differential 
methylation due to these variables that are correlated with the outcome of interest will often be the top 
results. This is usually not desired, as these results will therefore reflect differences due to these 
common phenotypes and not any interesting underlying biology. Any batch effects that are not 
previously removed should also be accounted for in the model, as well as any pertinent additional 
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phenotypes that do not have to do with the biology of interest – smoking in a study of heart disease, for 
example. 
Once linear models are created for each probe, additional data analysis can be performed. For 
example, the CHARM results discussed in chapters 2 and 3 of this thesis are created by using the 
“bumphunting” algorithm (Jaffe et al., 2012). Briefly, this method uses linear models to obtain a beta 
coefficient – summarizing the association of methylation with the phenotype of interest – for each 
probe. These coefficients are examined genome-wide, and a cutoff (usually around the 95% percentile 
of beta-coefficient values) is created. Loess smoothing is used to create average beta-coefficients 
between probes representing sites close to each other in the real genome. A sliding window method is 
then used to identify “bumps” – groups of CpGs close together on the genome where the average beta-
coefficients are above the cutoff. These represent areas of the genome where methylation is associated 
with the phenotype of interest across multiple nearby probes, a situation that may have more biological 
importance than differential methylation in individual CpGs. 
Ultimately, this is an exciting time for the field of epigenetics. Every month brings new 
epigenetic associations with diseases and specific phenotypes, allowing us a closer glimpse at the 
biological dysregulation that underlies disease. The remainder of this thesis deals with two current 




Epigenetics of obesity and insulin resistance 
 
The material presented in this chapter has been published in Cell Metabolism (Multhaup et al., 2015) 




Type 2 diabetes mellitus (T2D) is a metabolic disorder with a rapidly increasing worldwide 
prevalence. T2D affects 300 million adults worldwide and that number is predicted to rise to above 430 
million by 2030 (Chen et al., 2012). Although T2D has a significant genetic risk component, as 
determined by twin (Wareham et al., 2002) and genome-wide association (McCarthy, 2010) studies, the 
heritability estimate is only 21% when looking across all age groups (Almgren et al., 2011). These low 
heritability estimates, coupled with the rapid increase in worldwide prevalence, suggests a strong role 
for environmental risk factors. These environmental risk factors continue to be identified and defined 
(Chen et al., 2012), and recent work on the efficacy of Roux-en-Y gastric bypass (RYGB) surgery as a 
treatment for obesity has found that this procedure can have a profound positive effect on T2D-related 
metabolic indicators (Mingrone et al., 2012).  
Epigenetics, the study of non-DNA sequence based information that is replicated during cell 
division, such as DNA methylation, has been suggested as a natural integrator of genetic susceptibility 
and environmental exposure in common disease (Bjornsson et al., 2004). Epigenetics has also attracted 
considerable scientific and lay attention due to its dynamic nature across the lifespan (Feinberg et al., 
2010), association with common disease (Cui et al., 2003), and reversibility under targeted therapies 
(Sharma et al., 2010). Additionally, most common human diseases are explained to a very limited degree 
by known individual common genetic variants, with ~3.4% of risk profile score explained for psychiatric 
disorders like schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics, 2014), and 
~10.7% for T2D (Consortium et al., 2013). This combination of limited genetic causality, environmental 
influences and persistence over long time periods suggests a likely role for epigenetics in common 
human disease. However, epigenetic studies have their own limitations, including the need in most 
cases to use cells appropriate to the disease under study, confounding effects such as age, and the often 
considerable difficulty in designing replication sets, which are much easier in purely genetic studies 
because of the universality of the sample type (DNA from blood for SNPs or sequence). A number of 
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methodologies have been developed by our and other groups to adjust for cell type composition, 
confounding variables, and replication studies (which are typically much smaller) (Houseman et al., 
2012; Liu et al., 2013b; Montano et al., 2013). 
Genetic variants near the FTO gene have been linked to altered DNA methylation, though in this 
case the DNA methylation was not also associated with T2D (Bell et al., 2010). Analysis of known 
candidate genes in a small set of monozygotic twins discordant for T2D showed epigenetic changes at 
CDKN2A and HNF4A, but the study was not sufficiently powered for genome-wide agnostic discovery 
(Ribel-Madsen et al., 2012). Studies of pancreatic islets have found 254 methylation differences 
examining 5 deceased T2D patients and 11 controls (Volkmar et al., 2012) and 1,659 CpGs differentially 
methylated between 15 T2D and 34 non-diabetic controls (Dayeh et al., 2014). Similar changes have also 
been found in peripheral blood leukocytes from obese humans early after RYGB (Kirchner et al., 2014). 
RYGB is highly effective at restoring normal metabolic phenotypes in severely obese people (Kashyap et 
al., 2013). Moreover, interventions improving metabolic dysfunction in T2D and obesity influence DNA 
methylation when affected tissue is examined directly. One study that examined methylation in skeletal 
muscle from obese and lean subjects at 14 individually-selected loci found that methylation in obese 
subjects reverted to lean methylation levels after RYGB (Barres et al., 2013).  
Additionally, after RYGB, there is a greatly varied phenotypic response even within usually 
tightly correlated variables. For example, in a study of 66 obese and T2D who underwent RYGB with a 
follow-up of six years, glycated hemoglobin (HbA1c) and fasting glucose levels improved rapidly for six 
months after surgery and then leveled off, whereas total body weight loss and lipid indicators dropped 
but took 48 months to reach a nadir (Cohen et al., 2012). As methylation is a relatively stable epigenetic 
mark, differential rates of change in DNA methylation governing pertinent genes could help to explain 
this response to RYGB.  
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In the work presented in this thesis, myself and many others (hereafter referred to as “we”, 
please see Acknowledgements) have taken a novel approach in examining two species to identify 
candidate genes involved in obesity and T2D likely through epigenetic mechanisms. We first examined 
the epigenetic consequences of a high-fat diet in a carefully controlled experimental setting whereby 
obesity, due to excessive calorie consumption in the mouse, provides a close model for the insulin 
resistance and metabolic phenotypes that develop in human obesity and typically precede T2D. We then 
replicated across species—in humans—by analyzing adipose tissue from a cohort that both reproduces 
and reverses a phenotype similar to the obese mouse, i.e., severely obese versus lean subjects, as well 
as the same obese subjects pre- and post-RYGB. The use of samples from the same subjects pre- and 
post-RYGB allows a human isogenic comparison of the effect of obesity-induced metabolic disturbances. 
This cross-species approach exploits the power of evolutionary selection, whose mechanisms have 
survived the 50 million year separation between mouse and human, in a more comprehensive manner 
than simple replication from human set to human set, and may better identify functionally important 
environmental targets. We lastly stratified these cross-species obesity-associated regions using genetic 
association data from a large genome-wide association study (GWAS) for T2D to more directly link our 
obesity-derived phenotypes with human T2D. As a result of this approach, we are able to identify five 
genes with novel roles in insulin resistance, suggesting that this cross-species approach provides a 
powerful experimental system for identifying the genomic variation associated with common disease. 
Our approach moves from directly manipulable mouse models of insulin resistance and obesity 
to the more limited availability of clinical material from obese versus lean humans, with GWAS data 
serving as a final connection to T2D genetic liability. This is the opposite direction of much GWAS-
centered research, so we are describing the design in some detail here (Figure 1). To identify regions 
where DNA methylation levels were significantly associated with metabolic dysfunction in mice, we 
performed comprehensive genome-scale DNA methylation analysis on purified adipocytes from 12 
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C57BL/6 mice exposed to a high-fat diet and 12 C57BL/6 mice on a control low-fat diet. This diet-
induced obesity model induces many characteristics of human metabolic syndrome in mice, including 
obesity, insulin resistance hyperinsulinemia, hyperglycemia and hypertension (Surwit et al., 1988), 
purely as the result of an environmental change in diet, rather than a specific mutation. This model has 
gained wide acceptance in the metabolic field and is used to study not only blood chemistry, but distinct 
changes within and between multiple tissues controlling whole body glucose and energy homeostasis 
(Almind and Kahn, 2004; Surwit et al., 1995; West et al., 1995). For comprehensive genomic analysis, we 
used the Comprehensive High-throughput Array-based Relative Methylation (CHARM) method that in its 
current form can assay over 5 million CpG sites in mouse and 7.5 million CpG sites in human. In contrast, 
the very commonly used Illumina HumanMethylation450 microarray (Sandoval et al., 2011) assays 
485,000 CpGs and does not exist for the mouse. Methylation scores derived from array probes were 
clustered by genomic location and tested for significant phenotype association using a “bump hunting” 
algorithm we developed previously that models measurement error, removes batch effects and returns 
statistical measures of uncertainty for differentially methylated regions (Jaffe et al., 2012). 
We then assessed these DMRs in a cohort of obese and insulin resistant humans using adipose 
tissue from 11 obese and 8 lean patients pre-, as well as 8 obese patients post-RYGB surgery. Obviously, 
we can only consider genomic areas that map from mouse to human, yet over 85% of the regions 
showing differential methylation in mouse map to the human genome, suggesting the general 
importance of these genes in regulating metabolism affected by obesity. The results of this comparison 
could identify genes important in the pathogenesis of obesity and associated insulin resistance, but they 
also could identify genes whose sequence confers metabolic risk depending on environmental exposure. 
In order to identify the latter set, we then looked for genes showing significant enrichment for T2D 




We also identified DMRs distinguishing other tissues—hepatocytes, pancreatic islets, skeletal 
muscle, and hypothalamus—in mice exposed to high-fat vs. low-fat diet, and utilized other subjects and 
datasets to perform similar analyses in human pancreatic islets and hepatocytes. 
Across all five tissues examined—adipocytes, hepatocytes, skeletal muscle, hypothalamus and 
pancreatic islet—the strongest differences in DNA methylation associated with obesity were identified 
in adipocytes, with 232 or 448 differentially methylated regions (DMRs) depending on the commonly 
used Q-value cutoffs (controlling the false discovery rate, FDR, analogous to p-values corrected for 
genome-wide comparisons) of 0.05 and 0.10 (Table 1, full results in Table 2). As an example, in 
adipocytes from high-fat-fed mice, we found hypermethylation overlying the promoter of 
phosphoenolpyruvate carboxykinase 1 (Pck1, Figure 2A). PEPCK, the product of Pck1, catalyzes a rate-
limiting step in gluconeogenesis, is essential for lipid metabolism in adipose tissue, is known to be 
regulated by insulin, and has been linked to lipodystrophy and obesity in mice (Beale et al., 2004). We 
also found hypermethylation in a region 2kb from the promoter of the ATP-binding cassette sub-family 
D member 2 (Abcd2) gene in high-fat mice (Figure 2A). This gene is involved in the import of fatty acids 
and fatty acyl-CoA into the peroxisome (De Marcos Lousa et al., 2013). These genes have not previously 
been shown to be altered epigenetically in obesity or insulin resistance. 
In addition to the high-fat versus low-fat analysis, even more DMRs were detected when 
analyzing methylation differences related to the metabolic phenotypes of body weight, fasting glucose, 
and insulin and glucose tolerance test area-under-curve (ITT/GTT AUC) values (Table 2). One example of 
a mouse GTT-associated DMR is in the Fasn gene, which produces fatty acid synthase and is known to be 
involved in the development of obesity (Figure 2B) (Funai et al., 2013). Similarly, DNA methylation levels 
are highly correlated with body weight within the Nbea gene, which has been previously associated with 
body weight and feeding behavior (Figure 2B) (Olszewski et al., 2012). Most DMRs found were 
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significantly associated with more than one trait, which is not entirely unexpected as the phenotypes 
themselves are highly correlated (Figure 3) (Bando et al., 2001). 
We additionally examined DNA methylation in pancreatic islets purified from whole mouse 
pancreata, purified hepatocytes, skeletal muscle and hypothalamus in the lean and obese mouse 
models. While overall methylation changes were strongest in adipocytes, some genome-wide significant 
DMRs were also found in pancreatic islets and hepatocytes (Table 1, Table 2). A strong correlation was 
found between mouse body weight and DNA methylation in pancreatic islets. Figure 2C depicts two 
regions inside the Kcnj11 and Abcc8 genes where pancreatic islet methylation is positively correlated 
with body weight. These genes are known to be involved in insulin secretion in pancreatic beta-cells, 
and coding SNPs in KCNJ11 and ABCC8 have been strongly associated with T2D-related traits (McCarthy, 
2010) and with obesity in mice (Kanezaki et al., 2004). Together, these two genes jointly encode the β-
cell KATP potassium channel that mediates insulin release in pancreatic beta-cells (Flanagan et al., 2009). 
While mutations in these genes are direct clinical risk factors for T2D, the ABCC8 gene has not previously 
been shown to be epigenetically regulated in any obesity or insulin resistance model. 
While individual tissues had significant DNA methylation changes (Table 1), pooling all tissues 
together and surveying for DNA methylation changes in common yielded no significant results. There 
were, however, 29 genes corresponding to 33 DMRs in common between the individual tissue adipocyte 
and pancreatic islet DMRs, and these are listed in Table 3. 
The genome-wide significant mouse DMRs were near genes that were significantly enriched in 
metabolic and inflammatory pathways. We implemented gene set analyses to assess the overall 
biological importance of the DNA methylation changes we observed in mouse adipocytes and pancreatic 
islets using the Gene Ontology Enrichment Analysis and Visualization tool (GOrilla). The genome-wide 
significant adipocyte DMRs were near genes that were significantly overrepresented in lipid metabolic 
and immune/inflammatory pathways compared to the background list of genes represented on our 
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array, with enrichment Q-values < 9.7*10-3 (Table 4). Examining hyper- and hypo-methylated DMRs 
separately in high-fat-fed obese mice, we observed that the metabolic pathway enrichment was derived 
from genes near hypermethylated DMRs, while the inflammatory pathway enrichment was present 
mainly in genes near hypomethylated DMRs. Similarly, genes near pancreatic islet DMRs showed 
significant enrichment in secretory pathways. Examining only hyper- or hypomethylated pancreatic islet 
DMRs did not significantly alter the enrichment results compared with a joint analysis. 
Viewed globally, these results in dietary-induced obese mice track with known patterns of 
pathway change in obesity and insulin resistance. Inflammatory and immune related systems are known 
to be upregulated in adipocytes specifically in both obesity and T2D (Gregor and Hotamisligil, 2011; 
Hotamisligil, 2010). These pathways, however, have not previously been shown to be significantly 
associated with methylation changes in a diet-induced obesity phenotype. Additionally, recent work has 
shown adipose de novo lipogenesis downregulation associated with metabolic dysfunction, possibly 
mediated through the action of adipose-tissue derived lipid mediators (Roberts et al., 2009). Finally, 
islets isolated from human pancreatic donors in late-stage T2D have impaired insulin secretion in 
response to glucose stimulation (Del Guerra et al., 2005).  
We then tested for replication of the methylation results at nine DMRs in adipocytes and three 
DMRs in pancreatic islets in an independent set of 18 mice (Table 5). These DMRs were chosen so as to 
replicate both the largest and smallest genome-wide significant methylation changes, in order to 
determine whether even the least significant of our genome-wide results were valid. Mice used in the 
replication set were also reared on a high-fat diet but were separate from those used for CHARM. 
Adipocytes were extracted from these mice using the same procedures as for CHARM and assayed using 
bisulfite pyrosequencing, a sequencing based method of determining individual CpG methylation at high 
precision (Migheli et al., 2013). Nine regions found to be differentially methylated with CHARM were 
assayed by bisulfite pyrosequencing in adipocytes. Eight of these regions had at least one CpG showing 
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significant differential methylation in the same direction as detected by CHARM. For example, 
pyrosequencing was done to replicate the methylation differences found over the promoter of the Pck1 
gene (Figure 4A, left) and the Runx1 gene (Figure 4A, right). All five CpGs examined for Pck1 showed 
differential methylation mirroring that found in CHARM, with four of five at p-values < 0.05 (Figure 4A, 
bottom left panel). Similarly, all seven CpGs within the Runx1-associated DMR showed methylation 
changes in the direction indicated by CHARM, with five at p-values < 0.05 (Figure 4A, bottom right 
panel).  
Although these were fractionated cells under investigation, to further ensure that the results 
were not due to changes in the distribution of cell types, i.e. cell-type shifts in the high-fat fed obese 
mice resulting from the infiltration of immune cells into adipose tissue, we used quantitative PCR to 
characterize the expression of multiple macrophage- and adipocyte-specific markers in our purified 
adipocyte samples from low-fat-fed and high-fat-fed mice. We saw no significant change in the levels of 
expression of the macrophage (inflammatory) markers F4/80, Cd14, or Cd68, and we did see the 
expected obesity-related within-adipocyte changes of the adipocyte markers AdipoQ and Ccl2 (Table 6). 
To examine whether these methylation changes between high-fat- and low-fat-fed mice 
involved changes in the expression of nearby genes, we used quantitative PCR (qPCR) to examine the 
expression of thirteen genes near genome-wide significant DMRs (Figure 4B). Of these 13 DMRs, all but 
two were within the gene itself, one was 25kb upstream of Pcx, and one was 108kb downstream of 
Rgs3. These DMRs were chosen to span our set of methylation results from the largest to the smallest 
change that still survived genome-wide significance testing. We used qPCR to examine mRNA from the 
same adipocytes and mice that were analyzed by CHARM. Of the thirteen genes examined, nine showed 
significant changes in mRNA expression in the classical opposite direction to methylation changes in 
high-fat fed mice, e.g., lower mRNA expression in high-fat-fed mice with corresponding 
hypermethylation (Figure 4B). 
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Furthermore, we assessed whether these DNA methylation changes correlated with previously 
published genome-wide gene expression data (Xu et al., 2003). This was not a perfect comparison, as 
these previous studies examined whole adipose tissue whereas we used purified adipocytes and 
because the previously published data were from mice on a high-fat diet for 18-22 weeks versus 12 
weeks for our mice. Nevertheless, we saw a highly significant inverse correlation between diet-related 
methylation changes and diet-related gene expression changes (Figure 5A). This inverse correlation 
became more pronounced when examining only the genes near statistically significant promoter DMRs 
(Figure 5B). These results compare favorably to other functional analyses of discovered DMRs (Ji et al., 
2010; Kim et al., 2010a).  Taken together, these data show that we find robustly significant DMRs in mice 
that correlate with metabolic traits, that these DMRs replicate in separate animals, and that methylation 
at many of these regions appears to have a functional effect on gene expression. 
We reasoned that many functionally relevant DMRs in mice exposed to a high-fat diet serve an 
important metabolic function that would be conserved across species and often susceptible to similar 
environmental cues. Therefore, to determine whether the methylation changes observed in mouse 
adipocytes could be replicated in an evolutionarily divergent cohort, we performed CHARM analysis on 
human subcutaneous adipose tissues from 8 lean subjects and 14 obese sex- and age-matched insulin 
resistant subjects (Figure 1).  
We first examined the replication of mouse adipocyte DMRs in human adipose tissue from 
obese versus lean and pre- versus post-RYGB surgery. We performed our analysis at increasingly 
stringent levels of significance and calculated the probability of the degree of overlap occurring 
randomly. For example, we observed very strong overlap between DMRs in human obese versus lean 
adipose tissue and DMRs in high-fat-fed versus low-fat-fed mouse adipocytes (all p<10-15, Figure 6, 
rightmost five bars), showing that there is a strong correlation between areas that are regulated by 
methylation in metabolic dysfunction in both mice and humans. We also examined the overlap of 
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differential human adipose tissue methylation with other mouse tissues (Figure 6, leftmost 20 bars). The 
overlaps between these regions in non-adipose tissues were an order of magnitude less significant than 
with mouse adipocytes. These data suggest not only that methylation changes in obesity-induced insulin 
resistance are significantly conserved between species, but also that this epigenetic conservation is 
tissue-specific. 
Next, to actually replicate the mouse methylation changes in human (rather than merely assess 
overlap), we determined that out of a total of 625 genome-wide significant mouse adipocyte DMRs, 576 
had homologous regions on the human genome (hg19), calculated via the liftOver UCSC tool (Hinrichs et 
al., 2006), and 497 had human CHARM probes within 5kb. This is a remarkably high fraction (86.3%), 
suggesting that our assay method, CHARM, is highly comprehensive, but also that the location of CpG 
regions is strongly conserved in evolution. 
We then asked what fraction of these conserved methylation regions shows differential 
methylation in either of the two human comparisons. Of the 497 conserved DMRs, 249 (50.3%) showed 
significant differential methylation (p<0.05) between obese and lean people (Figure 1, Table 7). These 
numbers were similar when analyzing differential methylation before and after RYGB surgery, with 227 
mouse DMRs also being significantly differentially methylated in humans. As a final, restrictive step in 
using human methylation to validate our mouse results, we determined that 170 (68%) of these regions 
had a consistent direction of methylation change between high-fat fed obese mice and obese humans, 
such that if a particular region had higher methylation in high-fat-fed mice, that region would also have 
higher methylation in obese humans and vice versa. This may be overly restrictive, but our rationale for 
this criterion was that the change in methylation direction would be the same, even though not all 
methylation changes are inversely related to gene expression. Indeed, previous work has shown that 
DMRs in blood and iPSC DNA can be in the same location yet have opposite directionality in mouse and 
human (Ji et al., 2010). 
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When more restrictive human methylation significance cutoffs are used, the percentage of 
regions with consistent directionality (true positive rate) rises, but the total number of retained regions 
drops, with 67/77 (87%) directionally consistent at human obesity P-values <0.005, and 25/25 (100%) 
consistent at P-values < 0.0005 (Figure 7A). All 170 directionally conserved regions were associated with 
the metabolic phenotypes of fasting glucose, GTT, and/or ITT in addition to mouse diet status. 
Furthermore, 134 of these regions had a consistent effect directionality between obesity- and RYGB 
surgery-related methylation (e.g. higher in obesity and pre-surgery and vice versa), and a further 105 
had post-surgery methylation values that were in between lean and pre-surgery methylation values, i.e., 
regions where methylation in obese subjects appeared to revert towards a lean phenotype after surgery 
(enrichment p=2.8x10-3). 
In Figure 8, we present two examples of human regions that have significant methylation 
changes in adipose tissue, are in homologous regions of the genome as genome-wide significant mouse 
methylation changes, are directionally consistent with the mouse methylation changes, and have human 
post-surgery methylation levels that have moved from pre-surgery levels to be closer to the lean 
phenotype. These regions are over two genes; ADRBK1 (adrenergic, beta, receptor kinase 1, Figure 8A), 
and KCNA3 (potassium voltage-gated channel, shaker-related subfamily, member 3, Figure 8B).  
Next, we performed a similar mouse-human comparison in pancreatic islets by integrating our 
mouse pancreatic islet CHARM results with previously published Illumina Infinium  
HumanMethylation450 BeadChip array (“Illumina 450k”) (Bibikova et al., 2011) DNAm data on human 
pancreatic islets from T2D and control subjects (Shukla et al., 2011). Given the lower coverage on the 
Illumina 450k compared to the CHARM platform, only 160 of the 312 statistically significant (at q<0.05) 
mouse pancreatic islet DMRs had any Illumina 450k probes within 1 kb. However, these probes were far 
more associated with human T2D status than the rest of the probes on the array (p = 1.18x10-9, Figure 
7B) demonstrating that our mouse-derived islet DMRs for weight are enriched for potential epigenetic 
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alteration in human T2D. In addition, 52 of the 77 mouse DMRs (67%) with corresponding significant 
methylation differences in human T2D had directionally consistent methylation in the human data (odds 
ratio= 7.2, p=7.2x10-6). 
Similarly, though we observed only a limited number of significant hepatocyte DMRs in the 
mouse analysis, we assayed the regions corresponding to eight of these regions in human liver tissue 
using bisulfite pyrosequencing. Out of these eight regions, five of them (62.5%) had at least one 
corresponding human CpG with statistically significant methylation changes corresponding to body 
weight in humans in the same direction as the mouse DMRs corresponding with body weight in mice. 
Methylation in the remaining three regions assayed by pyrosequencing was not significantly associated, 
either positively or negatively, with body weight (Table 4). 
We also assessed whether the human adipose DNA methylation changes correlated with 
previously published human genome-wide gene expression data from obese and lean individuals 
(Maunakea et al., 2010). As with our mouse data, we saw a highly significant inverse correlation 
between obesity-related methylation changes and obesity-related gene expression changes (Figure 5A 
and Figure 5B, right panel). 
Ultimately, we find hundreds of large, biologically relevant changes in the methylome of 
adipocytes that correlate with diabetes- and insulin resistance-related phenotypes. These changes are 
genome-wide significant even after correction for multiple testing, correlate with gene expression, 
separate into relevent gene ontology pathways and, most importantly, are replicated over millions of 
years of evolution from mouse to human. This suggests that the dysregulation of metabolic pathways 
observed in obesity and diabetes are not the result of specific genomic SNPs or the dysregulation of 
individual genes, but are rather the epigenetically mediated hijacking of large segments of metabolic 





Interaction between genomics and epigenomics of T2D 
 
The material presented in this chapter has been published in Cell Metabolism (Multhaup et al., 2015) 
and is reproduced in part below. 
 
 
While we have found large-scale methylation changes in both mouse and human near 
biologically relevant genes, T2D is known to be a disease that is in part genetically determined. There 
are multiple different possibilities for how these two systems could interact. They could be separate, 
with the genome modulating inherent disease susceptibility and the epigenome being the instrument of 
environmental exposure within the cell; they could be perfectly enjoined, with changes in DNA 
methylation essentially being the messenger between genotype and phenotype; or there could be a mix 
of both approaches, with methylation reflecting independent environmental influences and mediating 
between those and the genetic landscape. While the only perfectly deterministic way to answer this 
question would involve creating genetic changes and seeing how the methylome and phenotype 
respond (something very difficult to do in humans!) what we can do is to observe the overlaps and 
correlations between these two layers of information and create hypothesis based upon how they 
interact. 
We incorporated data from human GWAS for T2D using two complementary approaches that 
allow further characterization of our candidate obesity-related DMRs and associated genes. GWAS 
summary statistics were obtained from the DIAGRAM (DIAbetes Genetics Replication And Meta-
analysis) T2D genome-wide association meta-analysis, comprising data from 12 separate GWAS studies 
totaling 12,171 T2D cases and 56,682 controls. These separate GWAS studies have each been corrected 
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for population structure differences, and the meta-analysis summary statistics (e.g. test statistics and p-
values per SNP) are available for public download (diagram-consortium.org). We first directly explored 
the association between genes with obesity-related DMRs and genes conferring clinical genetic risk for 
T2D by calculating statistical enrichment of the GWAS regions overlapping our DMRs. We counted the 
number of GWAS signals that overlapped at least one DMR and assessed statistical significance using a 
permutation procedure that resampled each GWAS signal 10,000 times across the mappable genome 
(see Methods section) (Collado-Torres and Jaffe, 2014). This procedure was performed on all significant 
DMRs for adipose and pancreatic islet data and then on the subset of DMRs that were directionally 
consistent across species. We found marginally significant enrichment for adipose DMRs, both with and 
without enforcing human directional consistency, among at least marginally significant GWAS signals 
(GWAS p-value cutoffs starting with p < 10-6, corresponding to enrichment p-values ranging from 0.0048 
to 0.0165), and non-significant enrichment for pancreatic islet DMRs (Table 8). Given the small number 
of directly overlapping regions, these results are likely strongly influenced by the strength of the TCF7L2 
signal. While much of the early literature on TCF7L2 focused on its role in pancreatic islets, there is 
growing evidence that extra-pancreatic effects may contribute to the T2D phenotype at this locus 
(Prokunina-Olsson et al., 2009) (Boj et al., 2012) (Nilsson et al., 2014). 
We further examined statistical enrichment in the context of regulatory networks involving 
genes implicated in GWAS. Although only one gene (TCF7L2) with genome-wide significant linkage to 
T2D in DIAGRAM was present in the directionally conserved cross-species adipose methylation results, 
the named genes at 23 genome-wide significant GWAS signals (usually the gene nearest to the lead SNP) 
were directly (one-step) connected to genes near DMRs either by transcriptional control or direct 
protein-protein interaction (Figure 9A). This amount of interaction represents significantly more than 
expected by random chance (p = 0.0206) (Figure 10), and demonstrates how genes implicated by 
methylation appear to be acting in the same pathways as genes implicated by GWAS. For instance, 
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PRC1, a regulator of cytokinesis, is associated with T2D by a genome-wide significant DIAGRAM result, 
but it has no known connection to any other gene implicated by genome-wide significant DIAGRAM loci. 
Its transcription, however, is regulated by FOXO1, an important transcription factor in gluconeogenesis, 
insulin signaling and adipocyte differentiation that we find to be differentially methylated in both mouse 
and human obesity. FOXO1 is in turn regulated by TCF7L2, one of the strongest GWAS results. These 
results (Figure 9A) illustrate how our methylation results fill and expand the T2D-GWAS interaction 
network to affect multiple pathways and multiple participants in those pathways simultaneously. 
Similarly, expanding beyond one-step connections, many of the 30 regions implicated by both 
methylation data and GWAS have extended connections to each other and act in the same pathways 
(Figure 9B). Furthermore, these extended pathways include many other genes implicated by both the 
mouse and human methylation analyses. For example, while Akt2 and Pck1 have no direct interaction, 
both of them interact with App, a gene implicated by genome-wide significant mouse methylation, and 
both of them either signal to or are regulated by CEBPB (CCAAT/Enhancer Binding Protein (C/EBP), 
Beta), which has nearby obesity-related methylated changes that are conserved and directionally 
consistent in both mouse and human and is capable of significantly affecting mouse response to high-fat 
diets (Rahman et al., 2012). 
Given these results, we sought to further filter our obesity-related DMRs down to the subset of 
genes likely associated with T2D. We hypothesize that DMRs that overlap associated marker SNPs for 
T2D can identify genes with epigenetic mechanisms of risk in adipose tissue and/or islets. As many of 
the DMRs overlapping GWAS T2D loci with low p-values implicate genes already known to be involved in 
T2D, obesity and related phenotypes, we therefore selected the subset of DMRs within genetic loci that 
had at least marginal statistical association with T2D clinical risk.  
This approach reduced the 170 regions of directionally consistent and evolutionarily conserved 
methylation change in adipose tissue using the SNP-level summary statistics of the DIAGRAM analysis 
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(Figure 1). In all, 30 cross-species and directionally conserved adipose DMRs directly overlapped with 27 
marker SNPs (or close proxies with linkage disequilibrium > 0.8) that had some evidence of association 
with T2D (at least p < 0.01, Table 9; see Methods). We also identified ten regions where conserved 
pancreatic islet DMRs overlap with DIAGRAM SNPs (Table 10).  
While the large number of genetic loci with nominal GWAS p-values makes finding low-level 
enrichment problematic, cumulatively the effects of these common SNPs have been shown to have 
biological importance and to explain large amounts of phenotypic variability beyond that described by 
genome-wide significant SNPs (Yang et al., 2010).  
In these 30 regions, not only have we connected methylation change to obesity-induced T2D 
phenotypes across two species, but the association with T2D-associated SNPs also provides a candidate 
mechanism for the methylation changes observed in human obesity and RYGB surgery. These 27 
identified SNPs could potentially explain up to 2.69% of genetic T2D liability, while only one of these loci 
reached genome-wide significance in DIAGRAM (Morris et al., 2012). Even excluding this GWAS-positive 
loci (TCF7L2), which explains 1.12% of the variance alone, the remaining regions could explain up to 
1.57% of genetic variance in T2D susceptibility. This analysis may not be completely independent of the 
previous characterization of liability (5.7% in Morris et al.) as genes identified here may lie in the same 
pathways as genes containing genome-wide significant SNPs, but it is in line with a polygenic 
contribution of lesser common variants to the disorder (Chatterjee et al., 2013).These data suggest that 
for at least some of these loci, genetic variation underlies changes in methylation that are causal for T2D 
risk. It is also possible that these regions are also susceptible to environmental factors that influence 
local methylation and that they therefore serve to integrate genetic and epigenetic effects.  
Note that this filtering-based approach is independent of assessing the statistical enrichment of T2D 
GWAS signal, either at SNP- or gene-level, within our cross-species obesity-associated DMRs, an 
approach commonly used with GWAS summary statistic data (Wang et al., 2010). Instead, we are 
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combining three lines of evidence – epigenetic dysregulation following high fat diet in mouse, epigenetic 
directional consistency in humans, and some evidence for clinical risk of T2D – to identify genes we 
believe are functionally implicated in the pathogenesis of T2D specifically through epigenetic 
mechanisms related to obesity. This approach therefore does not diminish the potential function of 
genes with GWAS-positive statistical association for T2D or our DMRs that do not overlap with GWAS-
associated SNPs for contributing epigenetically to obesity.  
We hypothesized that one mechanism by which DNA methylation and genetic variation 
contribute to T2D risk may involve enhancer activity, as a recent study found an enrichment of T2D 
sequence variants in pancreatic islet enhancer clusters (Pasquali et al., 2014). Using publicly available 
human enhancer maps in 86 independent cell and tissue types (Hnisz et al., 2013), we found that a 
striking proportion of DMRs mapped to adipose nuclei enhancers and super-enhancers (which had the 
largest degree of overlap across all cell types). While the background proportion of overlap for CHARM 
was 17.2% for adipose enhancers and 3.8% for super enhancers, 40.6% (69 overlaps, p = 1.58x10-15) and 
14.7% (25 overlaps, p=5.72x10-13) of the directionally consistent 170 regions, and 53.3% (16 overlaps, 
p=5.65x10-7) and 20% (6 overlaps, p=3.24x10-5) of the further 30 GWAS-associated regions above lie in 
adipose enhancers and super enhancers, respectively (Table 11). Thus, a major mechanism for 
methylation-mediated metabolic dysfunction is likely through epigenetic modification of enhancers. 
Note that most of these enhancers were not previously known to be related to T2D through 
conventional GWAS or other methods. 
In order to establish that our cross-species method can identify functional genes implicated in 
obesity, insulin resistance, T2D, and related research, we selected six genes to further investigate. Out of 
the set of 30 cross-species conserved DMRs that also overlay variants conferring at least marginal risk 
for T2D, 14 had no previously reported independent association with T2D. Of these 14 DMRs, 13 of 
them had obese human methylation that reverted toward the lean methylation phenotype after RYGB 
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surgery. As RYGB is a targeted, environmental therapy that improves multiple deleterious phenotypes 
including insulin sensitivity, we hypothesized that this subset of our results would be the most likely to 
have an effect on T2D- and obesity-related phenotypes. We then examined the physiological effect of 
altering the expression of these genes on adipocyte cell culture models using insulin-stimulated glucose 
uptake assays. This procedure can measure the responsiveness of adipocytes to insulin, an important 
measure of insulin sensitivity and resistance, and reduced glucose uptake has been linked to both 
obesity (Virtanen et al., 2002) and T2D (Martin et al., 1992). We assayed six 3T3-L1 adipocyte cell lines. 
Each line was stably expressing shRNAs or stably expressing expression plasmids against one of the six 
selected genes. In order to mimic the effects of a high-fat diet, genes hypermethylated in high-fat 
adipocytes were knocked down, and genes hypomethylated were overexpressed (with the exception of 
Car5a, which was knocked down as there was no suitable plasmid available at the time experiments 
began). Significant changes in glucose uptake were found in five of these six 3T3-L1 adipocyte cell lines. 
Three of these genes (Mkl1, Plekho1, and Tnfaip8l2) were hypomethylated in high-fat-fed mice 
and obese humans, had increased expression in at least one of the corresponding high-fat/obese gene 
expression cohorts, and, when overexpressed in 3T3-L1 adipocytes, decreased glucose uptake in 
response to insulin (Figure 11). Therefore, these three associations appear to follow the classic paradigm 
of methylation inversely correlating with gene expression leading to a change in phenotype.  Gstz1 also 
followed the classical paradigm in so far as it was hypermethylated in high-fat-fed mice and had 
decreased gene expression in obese humans, but 3T3-L1 adipocytes expressing shRNAs against this gene 
exhibited no significant change in glucose uptake. 
Two other genes (Tmcc3 and Car5a, which overlaps with the putative mouse transcript 
BC048644) had altered methylation in high-fat mice and obese humans, but had no significant 
corresponding gene expression changes (Figure 11B). We note that this proportion of methylation-gene 
expression correlation (4/6 DMRs having inverse correlation, 2/6 having no or positive correlation) is 
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almost exactly what is expected based on overall methylation-gene expression correlation both in this 
work (Figure 5) and in previously published literature (Barres et al., 2013). When the expression of 
Tmcc3 and Car5a was knocked-down in cell-culture adipocytes using shRNAs, however, there were 
significant changes in the insulin-stimulated glucose uptake. Presumably, methylation acts on the 
expression of these genes in some other manner than the classical inverse correlation paradigm, or, at 
least, does not alter transcription in baseline high-fat-fed mouse or obese human adipose tissue. 
In mouse, we identified 625 genome-wide significant differentially methylated regions (DMRs) 
that correlate with diet-induced obesity phenotypes in adipocytes. Of these regions, 249 had significant 
conserved methylation changes in human obesity, and 170 of these had the same direction of 
methylation change in both species. Thirty of these DMRs also overlapped with SNPs or nearby proxies 
that have been associated with human T2D genetic risk. These data show for the first time that DNA 
methylation changes in metabolic disease are conserved across species and that this conservation 
overlaps genomic regions where genetic polymorphisms have been associated with T2D. Our approach 
combines three lines of evidence – epigenetic dysregulation following high fat diet in mouse, epigenetic 
directional consistency in humans, and some evidence for clinical risk of T2D – to identify genes likely 
functionally implicated in the pathogenesis of T2D specifically through epigenetic mechanisms related to 
obesity. 
Of the 30 adipose DMRs that survive our filtering process, only two are near a gene (TCF7L2) 
that has previously been associated by conventional GWAS to T2D, though one other, ETAA1 has 
suggestive but not genome-wide significant associations with waist-hip ratio (Liu et al., 2013a). In the 
present study, while we use nominal P-value significance to identify human methylation and GWAS 
results, we first perform a multiple comparison correction in our initial set of mouse DMRs using a false 
discovery rate algorithm. As there is a growing awareness that the cumulative effect of common SNPs 
with low minor-allele frequency scores potentially explain large amounts of phenotypic variability 
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beyond that of genome-wide significant SNPs identifiable by GWAS (Yang et al., 2010), approaches like 
ours that can use alternative methods to identify significant areas of potential genetic risk are necessary. 
The unique SNPs in these regions potentially account for 2.76% of T2D genetic variance, almost half of 
which is known by purely genetic analysis and may be epigenetically mediated. 
We observed significant changes associated with five out of six genes assayed by insulin-
stimulated glucose uptake assay, a common indicator of insulin resistance. Screens using this assay and 
performed on sample sets not enriched for genes in gluco-insulinemic pathways have found a far 
smaller percentage of genes that will alter glucose uptake (~10%), (Tang et al., 2006), indicating that our 
method can successfully select potential targets with a much higher than random probability of affecting 
insulin sensitivity. Three of the genes that we found had altered glucose uptake fell into the classical 
inverse methylation-gene expression correlation: Mkl1, Plekho1 and Tnfaip8l2 were all hypomethylated 
in high-fat-fed mice and obese humans, had increased gene expression in corresponding subjects, and, 
when these genes were overexpressed in cell culture adipocytes, exhibited decreased glucose uptake in 
response to insulin, which would fit with the increased insulin resistance commonly observed in obesity 
and diabetes. While none of these genes have previously published roles in insulin resistance, all have 
been associated with inflammation, and inflammation as a gross phenotype has been previously 
associated with obesity and insulin resistance (Xu et al., 2003). More specifically, Mkl1 is known to be a 
transcriptional coactivator of serum response factor (SRF) (Cen et al., 2003), and SRF transcriptional 
activity has been associated with insulin resistance in skeletal muscle (Jin et al., 2011). While Tnfaip8l2 
has not been directly linked to obesity, insulin resistance or T2D, it is upregulated in diabetic rat kidneys 
(Zhang et al., 2010). Finally, PLEKHO1 has recently been shown to inhibit AKT/PI3K signaling (Zhang et 
al., 2014), a pathway known to be involved in insulin signaling. 
Two other genes, however, did not fit the classical inverse methylation-gene expression pattern. 
While Tmcc3 and Car5a exhibited hyper- and hypomethylation, respectively, in obese subjects, and their 
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knockdown with lentiviral shRNAs significantly altered insulin-stimulated glucose uptake assays, there 
were no corresponding gene expression changes in either human or mouse. A necessary role for Car5a, 
has been implicated for the optimal function of Pcx in liver (Lynch et al., 1995), and it could play the 
same role in adipose tissue. Pcx, also differentially methylated in our analysis, is the gene for pyruvate 
carboxylase, which converts pyruvate to oxaloacetate at the beginning of the de novo lipogenesis / 
glyceroneogenesis pathway, and in which Pck1 subsequently converts oxaloacetate into 
phosphoenolpyruvate. Taken together, Car5a could work with the already established Pcx and Pck1 in 
the alteration of de novo lipogenesis in adipocytes, a process essential for normal fatty acid metabolism 
in adipocytes (Beale et al., 2004). The role of Tmcc3 in the pathogenesis of insulin resistance in type 2 
diabetes and obesity is elusive; however, one recent poster presentation at the AACR 103rd Annual 
Meeting in 2012 (Wang, 2012) did report evidence that knocking down TMCC3 in breast-cancer stem 
cells inhibited Akt phosphorylation. If this finding replicates in adipose tissue (especially for Akt2), it 
could potentially explain the involvement of Tmcc3 in insulin-mediated glucose uptake. 
It is worth noting that as these genes did not contain common variants that passed the genome-
wide significant GWAS threshold, they would not have been identified by GWAS alone. Similarly, only 
three out of these five genes had significant gene expression changes. This functional assay illustrates 
how our method of combining cross-species methylation data with GWAS results for common SNPs can 
implicate genes that would not have been detected otherwise. For the two genes without significant 
gene expression changes, we hypothesize that DNA methylation may be affecting these two genes via 
one of the multiple pathways not involving blocking transcription factor binding at promoters, such as 
splicing (Shukla et al., 2011), the regulation of alternate promoters (Maunakea et al., 2010), or 
interference with repressor binding at non-promoter binding sites (Ando et al., 2000). Finally, with 
regards to the direction of glucose uptake change, we note that insulin signaling induces both positive 
and negative feedback within affected cells (Gual et al., 2005), and without a methylation-gene 
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expression candidate mechanism it is not possible to determine which feedback loop the methylation-
implicated genes are involved with. 
Collectively, our results have therapeutic implications for the treatment and prevention of 
metabolic disease. Of the three major classes of drugs commonly used to treat T2D, thiazolidinedione, 
biguanides and sulfonylurea, only thiazolidinediones act on adipose tissue. This class of drugs is known 
to affect the PPAR transcription factors. PPARG, in particular, is a master regulator of adipocyte function, 
and consequently, thiazolidinediones have been shown to affect many different areas of adipocyte 
function, including adipogenesis, insulin signaling, and inflammation (Arner, 2003). Thiazolidinediones, 
however, also produce significant deleterious edema in a subset of patients, presumably due to the 
targeting of PPARG in the kidney, as well as adipose tissue and the liver (Kiryluk and Isom, 2007). 
Antagonists against specific elements of the pathway downstream of PPARG that are known to be 
dysregulated in T2D and obesity, such as those we identify in this study, may prove to recapitulate many 
of the beneficial effects of thiazolidinediones without the non-specific side effects. 
Recent work in our laboratory has identified regions of the genome where DNA methylation acts 
to mediate a genetic effect on rheumatoid arthritis (Liu et al., 2013b), and the methylation changes in 
obese humans could potentially act in an analogous role. Our results in obese and insulin-resistant 
mouse models, however, identify methylation differences even between inbred mice, and thus are 
definitively the result of environmental stimuli rather than a genetic underpinning. The fact that we see 
many of these same methylation changes in obese humans, and that these changes are located over 
regions with known genetic links to T2D, implies that DNA methylation levels could be integrating and 
mediating genetic and environmental causes of metabolic disease at specific genomic loci. 
A previous study has investigated human adipose tissue from healthy individuals before and 
after a six-month exercise intervention, as well as adipose tissue from individuals with and without a 
family history of T2D. While no significant methylation differences were found to be associated with a 
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family history of T2D, exercise regimens in healthy individuals were associated to genome-wide 
significant methylation differences near 7,663 unique genes, and more specifically near 18 candidate 
genes associated with T2D by a genome-wide association study (Ronn et al., 2013). Of these 18 
candidate genes, only one (TCF7L2) overlaps with our results, suggesting that exercise-induced 
methylation change in healthy individuals and severe obesity induce differential methylation in mostly 
separate pathways. This locus was also previously implicated epigenetically in T2D but in a study of 
whole blood (Toperoff et al., 2012) and also was shown to contain a SNP that modified a CpG site and 
thereby associated with differential methylation in this region (Ronn et al., 2013). However, this 
particular variant was not the causal variant attributed to the GWAS signal (Gaulton et al., 2010).  
It is encouraging that many of the new genetic associations described here show pathway 
relationships to known genetic associations. We find that a large and significantly enriched number of 
the genes near directionally conserved cross-species DMRs had direct protein-protein or transcriptional 
connections to genes connected to T2D with genome-wide significance by the DIAGRAM GWAS meta-
analysis (Figure 9A). Moreover, many of the genes implicated in this study complement and expand 
pathways already known to be involved in T2D and insulin resistance. Furthermore, combining genes 
from all levels of this study creates regulatory networks that include genes with known involvement in 
T2D but also incorporate closely connected genes with no previously known obesity or T2D association 
that are shown to be involved with obesity and insulin resistance in this story.  To illustrate this point, 
we have assembled a diagram showing 21 genes implicated by both conserved methylation and 
DIAGRAM overlap (Figure 9B, red and green genes). While only two of these genes (or their products) 
interact directly, adding additional genes implicated by genome-wide mouse methylation and conserved 
cross-species methylation allows the creation of a regulatory network in which all of these genes 
interact with each other through some degree of separation. Some of these genes, such as FASN and 
APP, appear to be loci in this network, and could represent potentially important targets.  
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There are many approaches for, and important applications of, interrogating the association of 
functional and genetic elements using GWAS summary statistics (Consortium et al., 2012; Jostins et al., 
2012; Nicolae et al., 2010), but our approach is unique in its leverage of carefully controlled biological 
systems to directly integrate cross-species functional epigenomics and clinical genetic risk. Here we 
purposely stratify the 170 directionally consistent cross-species DMRs into the 30 that likely are most 
related to T2D and/or mediate genetic risk epigenetically, at least in adipose tissue. This work, of course, 
does not address or diminish the many GWAS associations that are not associated with methylation 
changes. Additionally, it is important to note that while we do not directly address the issue of 
methylation causality in this study, causality is, at the least, multi-tiered. Our new functional data 
certainly indicates that these epigenetic changes are functionally proximate to T2D-relevant phenotypes 
and therefore important for discovery and for clinical translation. Please note that the systems biology 
literature challenges conventional notions of causality as there is both positive and negative feedback in 
most complex living systems (Noble, 2012). 
The approach described in this study may have broad applicability to identify candidate genes 
that may better dissect mechanisms and potential routes of treatment in common human disorders, 
such as cancer and cardiovascular disease. The accessibility of a limited cohort of relevant patients with 
well characterized clinical materials before and after disease exposure is plausible for cross-species 
replication. This type of analysis can generate a reliable, functional candidate disease gene set that can 
be used to interrogate SNP datasets and lend additional support to specific targets that would not 
ordinarily pass the genome-wide correction threshold. The end result is a process that can integrate 
information from multiple complementary sources to identify potential targets essential for the 
pathogenesis of common diseases, such as obesity or T2D, that do not involve highly penetrant single 








Materials and methods used in Chapters 2 and 3 
 
 
Mouse Sample Preparation 
All animal protocols were approved by the Institutional Animal Care and Use Committee of The 
Johns Hopkins University School of Medicine. Male C57BL/6 mice were purchased from Charles River 
and housed in polycarbonate cages on a 12-h light-dark photocycle with ad libitum access to water and 
food. Mice were fed a high-fat diet (HFD; 60% kcal derived from fat, Research Diets; D12492) or the 
matched control low-fat diet (LFD; 10% kcal derived from fat, Research Diets; D12450B). Diet was 
provided for a period of 12 weeks, beginning at 4 weeks of age. At termination of the study, animals 
were fasted overnight and euthanized; tissues were collected, snap frozen in liquid nitrogen, and kept at 
−80°C until analysis. 
Intraperitoneal glucose and insulin tolerance tests 
Cohorts of mice were injected with glucose (1 g/kg body weight) or insulin (0.8 units/kg for LFD-
fed mice, 1.2 units/kg for HFD-fed mice). Animals were fasted overnight (16 h) prior to the glucose 
tolerance test.  For the insulin tolerance test, food was removed 2 h prior to insulin injection. Serum 
samples were collected by using microvette CB 300 (Sarstedt).  Glucose concentrations were determined 
at time of blood collection with a glucometer (BD Biosciences). Insulin and glucose tolerance tests were 
performed when mice were between 20 and 24 weeks of age.  
Mouse Hepatocyte Isolation 
A protocol for primary hepatocyte isolation was adapted from previously published methods 
(Berry and Friend, 1969; Li et al., 2010).  Briefly, mice were anesthetized and a catheter was inserted 
into the vena cava. The portal vein was then cut to allow liver-specific perfusion.  Mice were then 
perfused with PBS, followed by 100ug/mL Type I Collagenase (BD Biosciences) at a rate of 5 ml/min for 
10 min.  The liver was then removed and dissociated by straining through a 70 𝜇m pore nylon cell 
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strainer (BD Falcon).  The cells were then spun down and resuspended in William’s Medium E (Cellgro). 
Primary hepatocytes were then isolated by gradient distribution via centrifugation of the resuspension 
in a cold Percoll (GE healthcare) solution.  Verification of primary hepatocyte purity was assessed via 
quantitative real-time PCR for hepatocyte-specific genes compared to markers for endothelial and 
immune cells.  We observed >90% hepatocyte purity based on gene expression. 
Mouse Primary Adipocyte Isolation 
Mature adipocytes were isolated from mouse fat pads as previously described (Stahl et al., 
2002). Briefly, fat pads were finely chopped using scissors. Tissue was then dissociated in 2 mg/gram 
tissue Type II Collagenase (Sigma) in KRH buffer. The digestion was stopped by adding 10 %FBS (Atlantic 
Biologicals) to the mixture and cells were filtered through 100 μm pore nylon cell strainers (BD Falcon).  
The cells were then separated out by transferring the upper phase of cells to a new tube and washing 
with 5 mL of KR Buffer. The wash and resuspension was repeated 3 times and mature adipocytes were 
collected. Verification of mature adipocyte purity was assessed via quantitative real-time PCR for 
adipose-specific genes compared to markers for endothelial and immune cells. We observed >95% 
adipocyte purity based on gene expression. 
A third set of 9 high-fat diet mice and 9 low-fat diet mice were used for replicating CHARM 
results using pyrosequencing. Adipocytes were extracted and purified from these mice using the same 
method as used for CHARM. For the pancreatic islets, however, whole pancreases were obtained from 
the replication mice, stained for insulin using the Anti-Insulin + Proinsulin antibody [D3E7] (Biotin) 
(ab20756) (Abcam, MA, USA) kit, cryosectioned into 8µm sections, and then laser-capture 
microdissection was used to isolate pancreatic islets (PALM Microbeam, Carl Zeiss, NC, USA). 
3T3-L1 transduction and transfection 
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3T3-L1 cells were transducted with Sigma Mission™ lentiviral particles as per the manufacturer’s 
protocol. Briefly, cells were plated at 60% confluency and incubated for 18 hours in a humidified 
incubator. Media was removed and replaced by Opti-MEM (Invitrogen) with 8µg/ml Hexadimethrine 
Bromide (Sigma-Aldrich). Fifteen µl lentiviral particles were added and the plates were incubated for 18 
hours in a humidified incubator. Media was then removed and replaced, and on the following day media 
containing 10µg/ml puromycin (Sigma Aldrich) was added and the cells were cultured in puromycin 
thereafter. 
3T3-L1 cells were transfected with overexpression plasmids using Lipofectamine 3000 (Life 
Technologies) as per the manufacturer’s protocol. Briefly, cells were plated at 60% confluency and 
incubated for 18 hours in a humidified incubator. Lipofectamine 3000 (1.5µl per well containing cells) 
was diluted and mixed in 50µl Opti-MEM medium (Invitrogen). At the same time, 4µg plasmid DNA was 
diluted in 50µl Opti-MEM with 2µ P3000 reagent and mixed. The diluted Lipofectamine and plasmid 
DNA were then mixed, incubated for 5 min at room temperature, and distributed onto the plated cells. 
After 24 hours incubation, the media was replaced with growth media. After 48 hours, 500µg/ml 
Geneticin Selective Antibiotic (G418 Sulfate, Life Technologies) was added, and the cells were 
maintained in geneticin thereafter. 
Lentiviral particles used: Tmcc3 (TRCN0000126784, Sigma Aldrich), Gstz1 (TRCN0000103080, Sigma 
Aldrich), Car5a (TRCN0000114521, Sigma Aldrich), MISSION® TRC2 pLKO.5-puro Non-Mammalian shRNA 
Control Transduction Particles (Control, SHC202V, Sigma Aldrich). 
Overexpression plasmids used: Mkl1 (MC202660, Origene), Plekho1 (MC210507, Origene), Tnfaip8l2 
(MC203559, Origene), Cloning vector PCMV6-Kan/Neo (Control, PCMV6KN, Origene).  
Cell culture and glucose uptake assay 
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Knock-down and over-expression cell lines were maintained in Dulbecco's Modified Eagle 
Medium (Invitrogen) supplemented with 10% FBS (Invitrogen), 10 µg/ml puromycin and 500 µg/ml 
geneticin (G418) as selective antibiotics for the knock-down and overexpression lines, respectively. Two 
days after confluence, differentiation of the knock-down lines was induced by incubation with MDI 
medium (4 µg/ml insulin, 0.5mM Methylisobutylxanthine (IBMX), 1.0 µM dexamethasone) for 2 days 
and 4 µg/ml insulin for 5 days. Differentiation of the over-expression lines was induced with MDI 
medium and 1 µM rosiglitazone for 3 days and 4 µg/ml insulin for 3 days. After another 3-5 days of 
incubation with maintenance medium, 80%-100% differentiation was shown by lipid droplet 
accumulation in the cells. 
Glucose uptake assays were performed on differentiated knock-down and over-expression lines. 
After 2 h of incubation in serum-free DMEM, they were washed twice in pre-warmed PBS and placed in 
HEPES-buffered saline solution (25 mM HEPES, pH 7.4, 120 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.3 mM 
CaCl2, 1.3 mM KH2PO4, and 0.5% BSA) containing 10 nM or 100 nM insulin for 20 min. Then, 0.5 μCi/well 
2-deoxy-D-[3H]glucose (Moravek) was added for 5 min. The reactions were terminated by two ice-cold 
PBS washes. Cells were then incubated for 10 min with whole cell lysis buffer (20 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, 0.5% NP-40, and 10% glycerol). The lysates were transferred to scintillation vials 
containing Ecoscint scintillation fluid (National Diagnostics) and counted with a Beckman Coulter 
counter (model LS 6000SC). 
Clinical Cohort 
This study was approved by the Regional Ethics Committee of Stockholm. All participants 
provided informed oral and written consent. Clinical characteristics are shown for the obese men before 
and after RYGB surgery (n = 11, 8, respectively) and non-obese (normal weight) age-matched men (n = 
8). Full information for human subjects can be found in Table 12.  
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Human Sample Surgery and Subcutaneous Adipose Tissue Biopsies  
A standard laparoscopic RYGB with a 1 m Roux limb was performed. The patients were weight 
stable and not subjected to a preoperative weight loss period. Subcutaneous abdominal adipose 
biopsies (50–100 mg) were obtained from the obese and non-obese (normal weight) subjects. Biopsies 
were obtained at the beginning of RYGB surgery (obese subjects) or elective laparoscopic 
cholecystectomy (lean subjects) after the induction of general anesthesia. Only non-glucose-containing 
intravenous solutions were administered before the biopsy was taken during RYGB or elective 
cholecystectomy surgery after an overnight fast. Biopsies taken from the obese subjects 6 months after 
RYGB surgery were obtained under local anesthesia (5 mg/ml of lidocaine hydrochloride) in the morning 
after an overnight12 hour fast from the same surgical incision as the initial biopsy. Biopsy samples for 
DNA analysis were immediately frozen and stored in liquid nitrogen until analysis. The patients were 
prescribed a liquid diet for 1 month after the RYGB surgery and then solid food. All RYGB patients were 
prescribed multivitamin, B12, folic acid, vitamin D, and calcium supplementation once daily. Fat and liver 
biopsies were obtained at the beginning of RYGB surgery (obese subjects) or elective laparoscopic 
cholecystectomy (lean subjects) after the induction of general anesthesia. 
CHARM DNA methylation analysis 
Genomic DNA from all samples was purified with the MasterPure DNA purification kit 
(Epicentre) following the manufacturer’s protocol. Genomic DNA (1.5–2 μg) was fractionated with a 
Hydroshear Plus (Digilab), digested with McrBC, gel-purified, labeled and hybridized to a CHARM 
microarray as described (Ladd-Acosta et al., 2010). The mouse CHARM 2.0 array used in the analysis 
now includes 2.1 million probes, which cover 5.2 million CpGs arranged into probe groups (where 
consecutive probes are within 300 bp of each other) that tile regions of at least moderate CpG density. 
The human CHARM 3.0 array now includes 4.1 million probes, which cover 7.5 million CpGs. These 
arrays include all annotated and non-annotated promoters and microRNA sites on top of the features 
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that are present in the original CHARM method. We dropped 7 human arrays with <80% of their probes 
above background intensities, resulting in 14 pre-surgery obese samples, 8 post-surgery obese samples, 
and 8 lean samples that underwent DNA methylation analysis. The design specifications are freely 
available on our website (rafalab.jhu.edu). We then removed sex chromosomes to improve the batch 
correction methods.  
Subsequent pre-processing, normalization and correction for batch effects were performed as 
previously described (Jaffe et al., 2012). Briefly, we applied our “bump hunting” approach which involves 
a) performing linear regression at each probe, comparing DNA methylation levels versus a covariate of 
interest (e.g. high- versus low-fat diet), adjusting for surrogate variables (Leek and Storey, 2007), b) 
smoothing the regression coefficient for the covariate of interest across nearby probes and c) 
thresholding these smoothed regression coefficients across all probe groups, which forms differentially 
methylated regions (DMRs) representing adjacent probes with statistics above the threshold. Each DMR 
is summarized by its “area”, or the sum of the adjacent statistics above the threshold. We used the 
99.9th percentile of the smoothed statistics for each respective species, tissue and trait comparisons 
bump hunting analysis. Statistical significance was assessed via linear model bootstrapping, retaining 
surrogate variables, followed by bump hunting, which approximates full permutation (e.g. permuting 
trait, recalculating surrogate variables, then bump hunting) using much less computational time (Jaffe et 
al., 2012) 
Bisulfite Pyrosequencing 
Individual CpGs inside DMRs found as a result of CHARM analysis were chosen for validation 
using the MethPrimer software (Li and Dahiya, 2002). Genomic DNA (gDNA, 200 ng) from each 
replication sample was bisulfite treated using the EZ DNA Methylation-Gold™ Kit (Zymo research) 
according to the manufacturer's protocol. Bisulfite-treated gDNA was PCR amplified using nested 
primers, and DNA methylation was subsequently determined by pyrosequencing with a PSQ HS96 
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(Biotage). Artificially methylated control standards of 0, 25, 50, 75 and 100% methylated samples were 
created using mixtures of purified and SssI-treated whole genome amplified (WGA) Human Genomic 
DNA: Male (Promega). Primer sequences used for the bisulfite pyrosequencing reactions are available in 
Table 13. 
Quantitative PCR analysis 
Validated primers for all genes were taken from PrimerBank (Wang and Seed, 2003) and 
synthesized by Integrated DNA Technologies (Coralville, IA, USA). Exact primer sequences are available 
in Table 14. RNA was extracted with Trizol reagent (Life Technologies, Carlsbad, CA, USA), cDNA was 
created with Quantitect Reverse Transcriptase Kit (Qiagen, Venlo, Netherlands), and quantitative-PCR 
was performed with Fast SYBR Green (Applied Biosystems, Foster City, CA, USA) on a 7900HT Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA, USA). RNA levels were normalized to same-
sample 18S RNA levels. 
GO annotation 
We analyzed GO annotation using the GOrilla tool (Eden et al., 2009). Genes identified from our 
analysis were compared to a background of all genes detectable on that array to calculate enrichment.  
Whole-genome gene expression analysis 
Whole genome gene expression data for mouse and human analogues of our study was found 
and downloaded from GEO (Barrett et al., 2013). The mouse data was already pre-processed, and the 
human data was pre-processed using Robust Multi-array Averaging (RMA) from the Affy R library 
(Gautier et al., 2004). The gene expression data was then matched against the DMRs closest to 
corresponding genes and the log fold change (logFC) of the gene expression was plotted against the 
average value of the smoothed effect estimate within the DMR, and p-values were generated using t-
tests based on Pearson’s product moment correlation coefficient. 
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Enrichment between human and mouse DMRs  
The liftOver tool from the UCSC genome browser transformed the coordinates from two sets of 
human DMRs (obese versus lean, and pre- versus post- RYGB  surgery) from the hg19 human genome to 
the mm9 mouse genome, as implemented in the rtracklayer Bioconductor package (Lawrence et al., 
2009). The locations of the 249,094 probe groups on the human CHARM array were also lifted over to 
serve as the natural background for enrichment, of which 214,646 (86.2%) had any analogous sequence 
in mouse, and a further 109,234 (50.9%) were within 5kb of a mouse CHARM probe group. For each pair 
of DMR lists, one from the two lifted over human DMRs and another from the 25 mouse trait DMRs 
(Table S1), we calculated the number of DMRs at given within-specific p-value significance levels, and 
calculated the number that overlapped within 5kb across species. Enrichment tests were chi-squared 
tests based on the number of species-overlapping significant DMRs, then DMRs only significant within 
each species, and finally the number of lifted probe group (of the 109,234) that were not significant in 
either species (which creates a 2x2 table of the number significant in both species, significant in just 
human, significant in just mouse, and significant in neither species). This is analogous to creating a Venn 
diagram between significant human and mouse DMRs. 
Cross-species statistical analysis  
We combined significant adipocyte mouse DMRs (at FDR < 5%) across the five traits (glucose, 
GTT, ITT, weight, and diet) by retaining the maximal coordinates over overlapping cross-trait DMRs 
resulting in 625 independent DMRs associated with at least 1 trait in adipocytes in mouse. These regions 
were lifted over from the mouse mm9 genome build to the human hg19 genome build as implemented 
in the rtracklayer Bioconductor package (Lawrence et al., 2009), of which 576 had homologous regions 
in the human hg19 genome. These DMRs were annotated to the nearest human charm probe group 
based on the annotation within 5kb, leaving 497 DMRs. We then computed a difference and 
corresponding p-value in obese versus lean and then in obese humans pre- versus post RYGB surgery 
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using linear regression, and retained the minimum p-value, number of probes with p < 0.05, and the 
slope at the smallest p-value, within each of the 497 mapped DMRs. Directional consistency across 
species was higher methylation in obese compared to lean and positive association between DNA 
methylation levels and GTT, ITT, fasting glucose, body weight, and a high-fat diet. 
DIAGRAM GWAS analysis 
We next integrated GWAS results into the 497 mouse DMRs by obtaining publicly available 
results from the DIAGRAM meta-analysis (http://diagram-consortium.org/downloads.html; Stage 1 
GWAS: Summary Statistics download) with coordinates in genome build hg18. We then generated 
regions of high genotypic correlation by taking all SNP rs numbers with p < 0.01 (n=39,081) passing them 
through the SNAP tool using CEU 1000 Genomes Pilot 1 data (Johnson et al., 2008), obtaining proxy 
SNPs with R2 > 0.8 (n=167,055 unique  proxies), and recording the coordinate range of the proxies for 
each SNP. Overlapping per-SNP risk regions were merged if overlapping (n=7,946 genotypic risk regions) 
and the smallest p-value across all merged SNPs represented the p-value for the genotypic risk region. 
These genotypic regions were lifted over to hg19 coordinates for cross-species analysis as described 
above. We estimated the variance in disease susceptibility based on the algorithms provided in the 
Methods section of Morris et al (Morris et al., 2012) and from Wray et al (Wray et al., 2010) using 1000 
Genomes-derived risk allele frequencies and assuming a disease prevalence of 8% for a given collection 
of risk SNPs. 
We assessed potential enrichment between DMRs and the GWAS results using two 
complementary approaches – the first approach assessed the enrichment in genome location between 
DMRs and the LD blocks from the GWAS. This permutation-based enrichment test is performed on two 
lists of genomic regions (e.g. chr:start-end) that assesses the degree of overlap relative to the 
background genome. At a given GWAS p-value cutoff, we counted the proportion of GWAS signals that 
overlapped at least 1 DMR, and then generated background overlap by resampling the same number of 
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GWAS regions (and the same length distribution) 10,000 times from the mappable genome (e.g. the 
genome after removing coordinates corresponding to telomeres, centromeres and other gaps present in 
genome build hg19, available from UCSC). Empirical p-values for enrichment were calculated by 
counting the number of null proportions that were greater than the observed proportion. R code is 
available on GitHub (Collado-Torres and Jaffe, 2014). 
The second approach assessed enrichment in gene symbols based on all genes directly 
connected (one-step) to genes linked to T2D with genome-wide significance by the DIAGRAM meta-
analysis based on regulatory networks generated using QIAGEN’s Ingenuity IPA (Ingenuity® Systems, 
www.ingenuity.com). These sets (also known as interaction networks in Ingenuity) were able to be 
generated for 57 out of 59 genome-wide significant genes. Full interaction networks were not able to be 
retrieved for the remaining two genes, and these were excluded from the analysis. These interaction 
networks then had chemicals, groups, complexes and miRNAs filtered in order to limit the potential 
interacting partners to genes and protein products.  
We computed whether genes overlapping obesity-related DMRs were more likely to be 
associated with GWAS genes and their interaction networks. We first removed DMRs that were not 
within 10kb of a RefSeq gene, leaving 244 and 471 obesity-related DMRs in islet and adipose tissue 
respectively (from 312 and 576). Then we counted the number of GWAS-associated genes and their 
directly connected partners in the genes containing DMRs. This procedure was also performed after the 
cross-species conservation filtering step described above, leaving 44 and 146 conserved obesity-related 
DMRs overlapping genes. We obtained statistical significance based on a resampling analysis, where we 
resampled the same number of probes groups 100,000 times from all probes groups mapped to human 
genes on the mouse CHARM design by: 1) lifting the range of the coordinates of each probe group to 
hg19, 2) removing poorly lifted probes groups defined as greater than 1.5 times the longest (in bp) 
original probe group prior to lifting over, 3) assigning the nearest human gene to each lifted probe 
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group, and 4) dropping lifted probes groups not within 10kb of a human RefSeq gene. We counted the 
number of GWAS signals or their directly connected partners that overlapped the resampled genes in 
each iteration, and calculated an empirical p-value based on this null distribution. This procedure was 









Epigenetic changes in Coronary Heart Disease in the general population 
 
Coronary artery disease (CAD), also known as coronary heart disease (CHD) and ischemic heart 
disease (IHD), is the leading cause of death worldwide, representing 13.3% of all global mortality 
(Lozano et al., 2012). The lifetime risk of developing CHD has been estimated at one in two for men and 
one in three for women (Lloyd-Jones et al., 1999). While mortality due to CHD peaked in Western 
countries in the 1960s and 1970s (Cooper et al., 2000), CHD continues to spread in the developing world 
and in 2010, three fourths of global death due to CHD occurred in global and developing countries 
(Gaziano et al., 2010). 
Twin studies have estimated that 30-60% of CHD risk variation can be attributed to genetics 
(Marenberg et al., 1994). Currently, genome-wide association studies (GWAS) have identified over 50 
common genetic variants associated with coronary heart disease risk 
(http://www.genome.gov/gwasstudies).  Cumulatively, however, these loci only explain ~10% of CHD 
additive genetic variance (Schunkert et al., 2011). This low proportion of explained genetic risk is in line 
with other complex chronic diseases such as Type 2 Diabetes. 
The risk factor profile of CHD is complex, and environmental factors shown to contribute to CHD 
involve smoking, alcohol use, socioeconomic status, education and diet (Pearson et al., 2002) (Matthews 
et al., 1989). Similarly, biomarkers including diabetes status, hypertension, blood pressure, and 
hyperlipidemia have all also been associated with CHD (Khot et al., 2003). 
Epigenetics provides a possible mechanism to explain both the low effect size of GWAS risk 
variants as well as how genetics and environment can interact to produce disease phenotypes 
(Bjornsson et al., 2004). While there have been several studies that established links between global 
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DNA methylation levels and CHD or CVD (Kim et al., 2010b; Sharma et al., 2008; Wei et al., 2014), there 
has yet been very little research examining the links between methylation at specific genomic positions 
and CHD.  
Here we characterize whole blood genome-wide DNA methylation in 336 samples from an age- 
and gender-matched CHD case/control subset of the Framingham Heart Study using the Illumina 
Infinium 450k BeadChip array. Analyzing this paired case-control CAD cohort, we find over 20,000 
significant (p<0.05 CpGs). 
 
Chapter 4 Methods 
The Framingham Heart Study sample 
The Framingham Heart Study (FHS) is a community based longitudinal study of participants 
living in and near Framingham, MA, at the start of the study in 1948 (Dawber et al., 1951). The Offspring 
cohort was comprised of the children and spouses of the original FHS participants, as described 
previously (Kannel et al., 1979). Enrollment for the Offspring cohort began in 1971 (n=5,124), and in-
person evaluations occurred approximately every 4 to 8 years thereafter. The current analysis was 
limited to participants from the Offspring cohort who participated in the 8th examination cycle (2005-
2008) and consented to genetics research. DNA methylation data of peripheral blood samples collected 
at the 8th examination cycle were available in 2,741 participants.  
All participants provided written informed consent at the time of each examination visit. The 
study protocol was approved by the Institutional Review Board at Boston University Medical Center 
(Boston, MA).  
 
FHS phenotype and demographic covariate ascertainment 
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At the 8th in-person examination visit participants completed a questionnaire that inquired 
about their education, occupation, smoking status, and disease status. Highest levels of educational 
attainment was assessed by 8 categories—no schooling, grades 1-8, grades 9-11, completed high school 
or GED, some college but no degree, technical school certificate, associate degree, Bachelor’s degree, 
graduate or professional degree. These categories were collapsed into (1) high school degree or less, (2) 
some college, and (3) bachelor’s or graduate degree for the current analysis.  Smoking status was 
separated into current smokers, former smokers, and never smokers. Diabetes was defined as having 
fasting blood glucose ≥126 mg/dl or current treatment for diabetes. Cardiovascular disease was 
determined by a panel of 3 physicians, who reviewed participants' medical records, laboratory findings, 
and clinic exam notes.   
 
FHS DNA methylation measurement 
Peripheral blood samples were collected at the 8th examination (2005-2008). Genomic DNA was 
extracted from buffy coat using the Gentra Puregene DNA extraction kit (Qiagen, Valencia, CA) and 
bisulfite converted and cleaned using EZ DNA Methylation kit (Zymo Research Corporation, Irvine, CA) 
according to manufacturer’s instructions. DNA methylation quantification was conducted on the 
Infinium Human Methylation450 Beadchip (Illumina, San Diego, CA). Paired samples were bisulfite-
treated and hybridized together. The pairs were then randomly distributed across Infinium BeadChips 






Demographic characteristics of the total, filtered, and paired study samples were summarized in Table 1.  
Bivariate associations by CAD diagnosis were calculated and compared using student t-tests and linear 
model trend tests for continuous and categorical data, respectively (Table 2).   
 
Methylation data pre-processing 
Raw IDAT image files were processed in R (version 3.1) and methylation beta values were 
generated using the Bioconductor minfi package (version 1.12.0) with background correction (Aryee et 
al., 2014). Sample exclusion criteria included poor SNP matching of control positions (n=22), probe 
missing rate > 10% (n=8), outliers from multi-dimensional scaling (MDS) (n=34), outliers from 
methylated/unmethylated channel intensity scores (n=10) and sex mismatch (n=2). Probes were 
excluded if missing rate > 10% (n=684). Probes overlying annotated SNPs in the probe CG site or single-
base extension site were also removed (n=23,486). In total, 471 samples and 443,304 CpG probes 
remained for analysis.  
DNA methylation data was stratified-subset quantile normalized and principal components 
analysis (PCA) was used to assess potential batch effects, particularly of measured covariates such as 
sample position on array and hybridization date.  Batch effects related to hybridization date were 
removed using ComBat in the sva package (Leek and Storey, 2007). PCA on the ComBat adjusted matrix 
was used to assess the persistence of batch effects.   
Proportions of six major blood cell types (granulocytes, monocytes, B cells, NK cells, CD4T cells, 
and CD8T cells) were estimated from methylation data using cell type methylation reference panels 
(Houseman et al., 2012), as implemented through minfi.   
 
Single site discovery 
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 Individual differentially methylated probes (DMPs) were identified using the limma package 
(version 3.32.1) (Smyth, 2005).  Multivariable linear regression was used to identify individual CpG sites 
that were associated with CAD on the full, unpaired data set (n=448).  The primary model was adjusted 
for age, sex, granulocyte and CD4T estimated cell counts, and plate ID.  To estimate standard error, 
empirical Bayesian methods were used (Smyth, 2004).    Permutation-based P values to protect family 
wise error rates (FWER) across the genome were calculated based on 1,000 permutations of the CAD 
phenotypes. Similarly, at each CpG site, per-test P values protecting test-wise error rates (TWER) were 
calculated.   Model fit was assessed using P-P plots and estimated lambda inflation factors.  Enrichment 
of gene ontology biological processes was tested using the 1e-3 threshold.   
 We performed multiple sensitivity analyses across all probes. First we performed a full CAD risk 
factor multivariable linear regression model on the full dataset (N=448).  This model was adjusted for 
age, sex, cell type, plate, systolic blood pressure, body mass index, smoking status, alcohol consumption, 
diabetes status, and education level.  Secondary analyses also included conditional linear regression on 
the paired (n=336) data set.  This was implemented via the clogit function (Therneau, 1999) with CAD as 
the outcome variable, stratified by pairs, and adjusted for percent granulocytes and CD4T cells.  Likewise 
we performed a full risk factor conditional logistic regression model that also considered systolic blood 
pressure, body mass index, smoking status, alcohol consumption, diabetes status, and education level.   
 Comparison between probe overlaps in primary and secondary were assessed linear regression 
between probe p-values and beta-values. 
 
DMR discovery 
 We tested for differentially methylated regions (DMR) based on our primary model using the 
bumphunter package (version 1.5.5) as previously described (Jaffe et al., 2012).  We used 1,000 
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bootstraps to protect the relationships between covariates.  We set a maximum gap between CpGs of 
300 bp and queried regions with a quantile (0.995) based threshold. 
  
Results 
Study sample characteristics 
The association between DNA methylation and CHD was studied in a paired case-control subset 
of the Framingham Heart Study. After sample removal for quality control, one hundred and sixty-eight 
CHD cases were paired with controls by sex and age within 5 years. The median age of the cohort was 77 
years (IQR = 13) and consisted of 256 men and 90 women (Table 15). Median BMI was 28.26 (IQR = 6). 
Education was divided into tertiles (GED/post-high school education/Bachelor’s and higher degrees) 
with 123:100:126 in each category. The cohort consisted of 18 current smokers, 241 former smokers, 
and 87 never-smokers. Heavy alcohol use (greater than 6 drinks per week) was present in 92 individuals, 
moderate use (1-6 drinks per week) in 167 individuals, and 86 participants did not drink. Finally, doctors 
diagnosed 65 individuals with diabetes or high blood sugar. 
 As this was a paired study, there were no associations between sex or age and CHD status. Out 
of the other covariates, only education and smoking had significant associations with CHD status (p-
values 0.0449 and 5.28e-06, respectively, Table 16). BMI, alcohol use and diabetes or high blood sugar 
all had association p-values above 0.3. 
 In this study, we identify differentially methylated positions (DMPs) associated with CHD as 
categorized by at least one of the following criteria: 1) myocardial infarction diagnosed either with 
electrocardiogram or enzyme assay, 2) percutaneous transluminal coronary angioplasty procedure or 3) 
coronary artery bypass graft procedure. DNA methylation was assessed using the Illumina 450k 
HumanMethylation array. Data pre-processing, normalization and quality control procedures are 




Single site DNA methylation discovery 
 We find significant association between multiple CpGs and CHD status with 21,364 probes found 
to be differentially methylated (p<0.05). The top probes and the nearest genes are shown in Table 17. 
Approximately half (52%) of probes were hypomethylated. Several of the top differentially methylated 
CpGs are near genes that have previously been implicated in GWAS studies, such as PITX2, FLT1, 
PPAP2B, STK32B, and others are near closely related genes, such as PHACTR2 and PHACTR3 for the 
GWAS PHACTR1 loci. 
Regional DNA methylation discovery 
 As neighboring CpGs are known to have correlated methylation (Huynh et al., 2014), and as we 
have previously found multiple CpGs in specific regions linked to common disease (Multhaup et al., 
2015) we identified regions of the genome where multiple neighboring CpGs (within 300bp) were all 
associated with CHD status. We found 83 regions with area p-values < 0.05. These DMRs were also near 
several GWAS-implicated genes (APOB, HLA-DRB1). Out of the top 83 DMRs, only 5 were near genes also 
implicated by the DMP analysis. 
 
Discussion 
 This work is ongoing and currently in progress. While we find significant DMPs and DMRs, the p-
values associated with these do not remain significant after bonferroni and/or FDR multiple testing 
correction. There is some debate currently in the scientific community about the appropriateness of 
bonferroni as applied to methylation data. This is because the bonferroni correction assumes that each 
test is independent, and there is a large body of literature suggesting that CpG methylation levels are 
actually highly correlated between CpGs when the CpGs are within ~200 bp of each other. A recent 
Nature Neuroscience paper, for example, wrote “conventional methods for multiple-test correction, 
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such as those used in genome-wide association studies, are likely to be overly stringent and 
inappropriate given the non-independence of DNA methylation across multiple CpG sites and lack of 
inter-individual variation at many loci; in this study, we therefore report nominal P values” (Lunnon et 
al., 2014). 
 In practice, however, any reasonable publication will have either results that survive some 
recognized multiple testing correction OR stringent replication in separate cohorts. Therefore, in order 
to replicate our results, we are currently pursuing replication in three separate cohorts. Code has been 
provided to ensure that analytical methods are duplicated across cohorts and to reduce variation. 
Individual probe results from each cohort will be meta-analyzed together and the resulting meta-
analysis p-values will be adjusted by bonferroni correction. It is the hope of this author that these results 








Figure 1: Diagrammatic explanation of our experimental design and results. Left top and middle 
panels: Plots of mouse and human methylation, respectively. Each point represents the methylation 
level from an individual mouse or human at a specific genomic location, with smoothed lines 
representing group methylation averages. These points are colored blue for low-fat-fed mice and lean 
humans and red for high-fat-fed mice and obese humans. The methylation values range from 0 to 1, 
with 0 equal to minimum detectable methylation and 1 equal to maximum detectable. Left bottom 
panel: plot of significance of SNP association with T2D. Y-axis represents log p-values of the linkage. 






Figure 2. Genome-wide significant methylation changes related to diet-induced obesity in C57BL/6 
mice. (A) Two genome-wide significant DMRs located at Pck1 (left) and Abcd2 (right) are 
hypermethylated in adipocytes purified from mice raised on a high-fat diet. Each point represents the 
methylation level in adipocytes from an individual mouse at a specific genomic location, with smoothed 
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lines representing group methylation averages. These points are colored blue for lean mice and red for 
obese mice. (B) Body weight (grams) and glucose tolerance (AUC) are associated with methylation in 
adipocytes at genome-wide significant levels at the Fasn (left) and Nbea (right) genes, respectively. Each 
point in the top panels represents one probe, with the y-axis representing the Pearson correlation 
coefficients of the probes with the analyzed phenotype. Dotted lines represent the extent of the DMR as 
generated automatically via CHARM. The bottom panels display gene location information for the 
chromosomal coordinates on the x-axis. (C) Body weight (grams) is positively associated with 
methylation in pancreatic islets at genome-wide significant levels at the Kcnj11 (left) and Abcc8 (right) 
genes. For all insets, the y-axis represents methylation, the x-axis displays the specific phenotype 
associated with methylation in the larger plot, and each point represents the association of the average 






Figure 3. Correlation of metabolic traits in diet-induced obesity mouse model. Correlations between 
the mouse traits observed over time. Mouse weight, fasting glucose levels (collected at the time of 
glucose tolerance test), and insulin tolerance test and glucose tolerance test area-under-the-curve 
scores are plotted and correlated against each other. Correlation coefficients and p-values for the linear 






Figure 4. Replication of mouse methylation changes in additional mice, and associated gene 
expression changes. (A) Methylation changes observed after CHARM analysis at two genome-wide 
significant DMRs located at Pck1 (left) and Runx1 (right) are replicated in independent samples from 9 
high-fat and 9 low-fat mice using bisulfite pyrosequencing. Red boxes indicate CpGs assayed in 
pyrosequencing. For the lower pyrosequencing plots, the y-axis represents methylation, and individual 
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CpGs are plotted along the x-axis. Purple dots represent controls artificially methylated to have 0, 25, 
50, 75 and 100% methylation. (B) Gene expression changes for genes near genome-wide significant 
mouse adipocyte DMRs. RNA levels were normalized to same-sample 18S RNA measurements and are 
displayed as [CT (high-fat samples) – CT (low-fat samples)]2. The direction of the genome-wide significant 
CHARM DMR closest to the gene is denoted below the gene names; + and − represent regions hyper- or 







Figure 5. Correlation of methylation and gene expression in mouse and human adipose tissue. This 
figure shows the relationship between methylation and gene expression in both mouse and human 
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adipose tissues. Gene expression data was downloaded from GEO (see Materials and Methods) and 
plotted against mouse adipocyte and human adipose tissue CHARM data. Y-axes are the logarithm of 
the fold change (logFC) of the gene expression in high-fat-fed mice and obese humans versus low-fat-fed 
mice and lean humans. X-axes are the DNA methylation values calculated by CHARM (Table S1) for the 
high-fat versus low-fat mouse and obese versus lean human comparisons. Here, higher values indicate 
hypomethylation in high-fat / obese samples. P-values are for Pearson product-moment correlations 







Figure 6. Significance of methylation change overlap between mouse and human tissues. In this figure, 
all 25 mouse analyses (x-axis) are compared against the human adipose obesity analysis. Values plotted 
represent the largest –log(p-value) for chi-squared tests for the overlap for all DMRs with nominal p-







Figure 7. Consistent mouse-human methylation changes. A) For each square, the proportion of 
conserved mouse and human regions that had directionally consistent methylation changes in adipose 
tissue between species was calculated. Regions were required to have mouse and human methylation 
changes at or below the indicated Q-value for mouse and P-value for human. The color indicates the 
proportion of directionally consistent regions, with darker colors indicating a higher proportion. B) The 
observed versus expected T-statistics for the proportion of overlap between the CHARM pancreatic islet 
mouse methylation data and the previously reported Illumina Infinium 450k BeadChip pancreatic islet 







Figure 8. Overlapping methylation changes in human and mouse adipose tissue. Two genome-wide 
significant DMRs found in mouse adipocytes over Adrbk1 (A, top) and Kcna3 (B, top) are shown along 
with the corresponding methylation changes in human adipose tissue in (A, bottom), and (B, bottom). 
For the panels denoting methylation, each point represents the methylation level from an individual 
mouse or human at a specific genomic location, with smoothed lines representing group methylation 
averages. These points are colored blue for low-fat-fed mice and lean humans and red for high-fat fed 
mice and obese pre-surgery humans. Purple denotes samples from obese humans post-RYGB surgery. 
The methylation values range from 0 to 1. Below each methylation plot is a panel showing genomic 








Figure 9. Diagrammatic representation of the interactions between epigenetically conserved and 
genetically-associated genes implicated in this study. Generated using QIAGEN’s Ingenuity IPA 
(Ingenuity® Systems, www.ingenuity.com), these diagrams represent the connections between genes 
implicated in our analysis of adipocytes and adipose tissue. A) All genes with genome-wide significant 
linkage to T2D in the DIAGRAM meta-analysis were connected to genes near directionally and 
locationally conserved DMRs. Genes with no connections were dropped. B) Starting with the set of 30 
genes near directionally conserved cross-species DMRs that also overlapped genes with nominally 
significant T2D GWAS association, this network was grown by adding genes near species-conserved and 
mouse-only genome-wide significant DMRs in order to represent one potential regulatory network. The 
genes are colored as follows: —genes showing conserved differential methylation in mouse and 
human diet-induced diabetic phenotypes, with genetic T2D risk loci association (Table 3); —genes 
with a possible functional role in insulin sensitivity assayed by insulin-stimulated glucose uptake in this 
paper (Figure 6); —genes from the DIAGRAM meta-analysis that are genome-wide significant; 
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—genome-wide significant mouse DMRs that were conserved and directionally consistent in 
human obesity ( Table S4); —genome-wide significant mouse DMRs that are not also conserved 








Figure 10. Enrichment of connections between genes implicated by methylation and genome-wide 
significant GWAS genes. This figure shows expected and observed connections and (both direct protein 
interactions and transcriptional control) and overlap between genes near species-conserved adipose 
and islet DMRs and genes with genome-wide significant linkage to T2D in the DIAGRAM GWAS meta-
analysis. The set of all possible one-step connections to the DIAGRAM GWAS genes was pulled from the 
Ingenuity Knowledge Base, and the GWAS genes themselves were added. 100,000 permutations of 
random genes near DMRs were overlapped with this set, and the number of overlaps from the 
permutations are represented by the histograms. The actual number of observed DMR-GWAS 
connections is denoted by the vertical red line, and the p-values represent permutation p-values for the 








Figure 11. Overexpression and shRNA-mediated knock down of selected genes in 3T3-L1 adipocytes. 
Selected genes from the set of 30 species conserved and T2D-SNP overlapping adipose DMRs were 
either stably overexpressed (A) or knocked down with shRNA (B) as noted. After differentiation into 
mature adipocytes, these cell lines were then subjected to insulin-stimulated glucose uptake assay. 
Glucose uptake is plotted as fold difference from normal, and significance was determined by two-way 
ANOVA modified by Bonferroni correction denoted as follows: * p<0.05, ** p<0.01, *** p<0.001.  (C) 
DNA methylation and gene expression levels for high-fat-fed mice and obese human versus low-fat-fed 
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mice and lean humans (e.g., “↓“ indicates hypomethylation / lower gene expression in high-fat-fed and 
obese compared to low-fat-fed and lean). Bold arrows indicate significant changes; non-bold arrows are 











Table 1. Genome-wide significant mouse DMRs 
Tissue Analysis Q-val < 0.05 Q-val < 0.1 
Adipocytes 
Diet 232 448 
Weight 183 288 
Fasting Glucose 235 571 
GTT 0 3 
ITT 294 419 
Islets 
Diet 4 4 
Weight 446 495 
Fasting Glucose 0 0 
GTT 0 0 
ITT 0 0 
Hepatocytes 
Diet 0 0 
Weight 6 25 
Fasting Glucose 0 0 
GTT 0 0 
ITT 2 2 
Hypothalamus All Comparisons 0 0 
Muscle All Comparisons 0 0 
Q-values generated based upon comparison of observed DMR areas to areas generated by 1000 random 




Table 2. See Appendix 1 
Table 2. Mouse comprehensive high-throughput array-based relative methylation (CHARM) results, 
related to Table 1. These tables show the results of our CHARM analysis for the five assayed mouse 
tissues against the five measured metabolic phenotypes of diet, fasting glucose, mouse weight, glucose 
tolerance test and insulin tolerance test. Listed in each table are the genomic coordinates for each 
differentially methylated region (DMR), the average value of the smoothed effect estimate within the 
DMR (value), the number of probes in the DMR (nprobes), the statistical area (nprobes * value, area), a 
p-value for the difference in methylation at each DMR (pval_pool), family-wise error rate-corrected p-
values (pval_fwer), q-values derived from false discovery rate (see methods, qval_pool), the gene 
symbol and RefSeq annotation of the nearest gene, and multiple parameters describing the physical 
relationship of the DMR to the gene in the genome. As “% change” we also note the largest change in 
beta-value for any CHARM probe within the listed DMR. These are roughly the inverse logit of the scores 
from the value column with the surrogate variables regressed out, and are the numbers used to 
generate our plots. For diet analyses, these were differences between the average of samples from the 
low-fat and high-fat groups, and for continuous variable analysis these were differences between the 





Chr Start End Width qval Gene relation distance 
chr1 25111126 25111547 422 0.015 Clic4 inside 26857 
chr1 64061530 64062519 990 0.006 Pgm2 inside 1768 
chr1 1.01E+08 1.01E+08 465 0.005 Dbt inside 1015 
chr1 2.3E+08 2.3E+08 415 0.026 Galnt2 inside 33499 
chr2 1.69E+08 1.69E+08 160 0.042 Lass6 inside 117391 
chr8 17529635 17529755 121 0.047 Mtus1 inside 28971 
chr10 97517128 97517433 306 0.032 Entpd1 inside 1149 
chr10 1.3E+08 1.3E+08 447 0.005 Ptpre inside 114341 
chr12 11812172 11812279 108 0.022 Etv6 inside 9226 
chr12 1.25E+08 1.25E+08 470 0.006 Ncor2 inside 126377 
chr12 1.26E+08 1.26E+08 234 0.035 Aacs inside 19023 
chr17 40142289 40142472 184 0.032 Dnajc7 inside 27020 
chr17 48838267 48838764 498 0.036 3300001P08Rik downstream 35690 
chr5 34655547 34655935 389 0.029 Rai14 promoter 1628 
chr5 34687673 34687965 293 0.029 Rai14 inside 23832 
chr5 77803248 77803367 120 0.03 Lhfpl2 inside 118687 
chr5 1.07E+08 1.07E+08 257 0.011 Efna5 inside 96616 
chr5 1.07E+08 1.07E+08 438 0.006 Efna5 inside 64136 
chr7 47672033 47673452 1420 0.006 Tns3 upstream 24418 
chr7 1.51E+08 1.51E+08 177 0.035 Nub1 inside 553 
chr14 89707672 89708616 945 0.009 Foxn3 inside 192777 
chr3 72870608 72870903 296 0.036 Shq1 inside 25788 
chr3 72896699 72897027 329 0.047 Shq1 inside 466 
chr16 30455438 30455975 538 0.005 Sephs2 inside 1221 
chr16 56137894 56138256 363 0.006 Gnao1 upstream 85203 
chr16 85376056 85376680 625 0.005 Gse1 upstream 144355 
chr21 37412563 37413036 474 0.006 Setd4 inside 17406 
chr11 27473339 27473770 432 0.009 Lgr4 inside 18196 
chr11 27490752 27491523 772 0.01 Lgr4 inside 2692 
chr11 57067776 57068975 1200 0.005 Tnks1bp1 inside 20866 
chr15 61136559 61136807 249 0.024 Rora inside 381025 
chr15 62343394 62344034 641 0.005 Vps13c inside 7451 
chr4 1.14E+08 1.14E+08 773 0.005 Larp7 downstream 232193 
 
Table 3. Adipocyte DMRs with genes in common between adipocyte and pancreatic islet analyses. 
These are the adipocyte DMRs with Q-values < 0.05 from Table 1 that are near genes that were also 






Table 4: Gene ontology for genes near DMRs 







triglyceride metabolic process 9 47 3.33E-04 
acylglycerol metabolic process 9 56 8.23E-04 
neutral lipid metabolic process 9 58 7.51E-04 
positive regulation of cholesterol storage 4 6 2.15E-03 
low-density lipoprotein particle clearance 4 7 3.96E-03 
cellular carbohydrate metabolic process 11 131 9.12E-03 
Adipocyte Hypomethylated 
DMRs 
regulation of response to stimulus 81 2173 3.13E-05 
neutrophil chemotaxis 8 32 7.50E-04 
positive regulation of response to stimulus 48 1110 5.10E-04 
cell activation 23 334 4.70E-04 
myeloid leukocyte activation 10 59 4.13E-04 
immune system process 38 784 3.70E-04 
Pancreatic Islet DMRs 
regulation of cellular process 160 7177 4.70E-02 
regulation of biological process 166 7610 5.20E-02 
regulation of peptide hormone secretion 11 129 5.15E-02 
regulation of peptide secretion 11 134 5.54E-02 
regulation of insulin secretion 10 111 4.74E-02 
 
single-organism cellular process 179 8479 4.16E-02 
Genes near genome-wide significant DMRs (q-value <0.05) for adipocyte/fasting glucose and pancreatic 
islet/body weight associations were submitted to the Gene Ontology enRIchment anaLysis and 
visuaLizAtion tool (GOrilla) along with a background of all the genes possible to find on the applicable 
array. The list of genes found in adipocytes was first divided into hypomethylated and hypermethylated 
groups depending on the status of the corresponding DMR. Here, hypermethylation refers to areas 











Pyro CpG 1 High-
Fat 
Pyro CpG 1 Low 
Fat 
Adipocytes Chpt1 78.88 44.32 93.3 66.04 
Adipocytes Stap1 32.16 55.37 36.16 51.2 
Adipocytes Pscdbp 38.44 68.24 46.8 66.3 
Adipocytes Pck1 73.23 45.6 60.9 33.7 
Adipocytes Runx1 31.47 58.93 45.13 58.31 
Adipocytes Fasn 77.57 46.63 66.09 51.24 
Adipocytes Dguok 69.12 47.16 63.8 54.87 
Adipocytes Liph 71.81 55.24 66.5 43.88 
Adipocytes Axin2 58.6 36.98 56.43 34.28 
 
Pyro CpG 1 P-
value 
Pyro CpG 2 High-
Fat 
Pyro CpG 2 Low 
Fat 
Pyro CpG 2 P-
value 
Pyro CpG 3 High-
Fat 
0.029 88.6 54.5 0.017 90.72 
0.03 40.67 67.12 0.0042 48.81 
0.03 52.4 78.8 0.019 54.09 
0.0019 71.95 52.33 0.0012 65.2 
0.18 50.8 73.94 0.026 50.21 
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0.32 70.95 53.14 0.24 83.24 
0.26 55.5 36.4 0.03 49.8 
0.039 77.56 44.87 0.0077 59.57 
0.027 50.5 33.58 0.17 50.1 
 
Pyro CpG 3 Low 
Fat 
Pyro CpG 3 P-
value 
Pyro CpG 4 High-
Fat 
Pyro CpG 4 Low 
Fat 
Pyro CpG 4 P-
value 
54.47 0.0089 69.7 42.03 0.039 
71.46 0.014 50.98 76.35 0.015 
80.1 0.012 55.68 78.242 0.025 
38.9 0.003 70.1 47.6 0.011 
73.91 0.018 52 69.03 0.099 
47.03 0.022 95.05 81.26 0.22 
37.55 0.093 63.8 41.2 0.0069 
34.74 0.026 67.88 41.17 0.015 
25.4 0.064 37.95 30.88 0.52 
 
Pyro CpG 5 High-
Fat 
Pyro CpG 5 Low 
Fat 
Pyro CpG 5 P-
value 
Pyro CpG 6 High-
Fat 




65.52 34.58 0.038 73.86 35.44 
43.96 66.49 0.012   
     
75.27 56.88 0.061   
51.6 71.5 0.048 45.56 63.8 
     
75.27 56.88 0.061 55.53 36.41 
59.75 36.68 0.062 55.33 35.89 
58.09 41.36 0.069 68.91 80.2 
 
Pyro CpG 6 P-
value 
Pyro CpG 7 High-
Fat 
Pyro CpG 7 Low 
Fat 
Pyro CpG 7 P-
value 
Pyro CpG 8 High-
Fat 
0.018 73.94 45.8 0.077 68.63 
     
     
     
0.03 37.54 57.65 0.011  
     
0.03 49.88 37.55 0.094  
0.15 64.49 40.96 0.076 59.85 
0.18     
 














Tissue Nearest Gene 
(Mouse) 
CHARM value (derived from regression 
beta) 
CpG 1 Pyrosequencing 
Slope 
Hepatocyte Scd1 0.095453437 0.4194 
Hepatocyte Fermt2 -0.07619625 -0.0294 
Hepatocyte Atp6v0a1 -0.074216772 -0.02607 
Hepatocyte Arhgap29 -0.073105365 -0.2179 
Hepatocyte Scd1 0.076948689 0.1306 
Hepatocyte Masp1 -0.078898672 -0.0006339 
Hepatocyte Elovl5 0.067301744 0.2199 
Hepatocyte Tmem140 -0.083317234 0.01515 
 
CpG 1 Pyrosequencing CpG 2 Pyrosequencing CpG 2 Pyrosequencing CpG 3 Pyrosequencing 
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p-value Slope p-value Slope 
0.016 0.6214 0.026  
0.38    
0.024 0.1307 0.43  
0.012 -0.0122 0.82  
0.018 0.003109 0.95 0.244 
0.68 -0.0008258 0.9  
0.089 0.2955 0.025 0.282 
0.87    
 











Table 5. Mouse replication results. This table contains the results of our pyrosequencing assays to 
replicate our CHARM results in separate samples. For adipocyte measurements, this table presents the 
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levels of methylation in mouse CHARM, corresponding pyrosequencing results, and the p-value 
corresponding to a two-tailed t-test for difference between the pyrosequencing methylation values from 
high-fat-fed and normal chow-fed mice. For the hepatocyte results, this table presents the average value 
of the smoothed effect estimate for weight versus methylation within the DMR in mouse CHARM, the 
slope of the correlation between methylation and the outcome derived from pyrosequencing in 





Table 6. Tissue Purification qPCR results 
Gene Fold change (high fat/low 
fat) 
SD (SD_high_fat - 
SD_low_fat) 
Pval (true fold change is 
not 0) 
Adipoq -1.41 0.4 0.039 
Pparg -0.58 0.3 0.167 
Ccl2 1.29 0.32 0.043 
Albumin -0.08 1.32 0.476 
CD68 1.69 0.9 0.174 
Coro1a 0.02 1.41 0.494 
F4/80 0.06 0.64 0.463 
CD14 0.27 0.38 0.341 
 
Table 6. Results of qPCR assay to test adipose tissue purification, related to Figure 3. This table shows 





Table 7. Conserved mouse/human adipose tissue DMRs 
Chr Start End Human p-val Human beta 
chr1 6804060 6804159 0.05396806 -0.127370809 
chr1 19804495 19805076 0.009584786 -0.102400227 
chr1 23171771 23172254 0.163730493 -0.037281993 
chr1 27681877 27682185 0.017716616 -0.077604526 
chr1 36191885 36192039 0.239591101 -0.036206241 
chr1 37838402 37839079 0.378536274 -0.015552746 
chr1 48351513 48351750 0.000271516 0.138474484 
chr1 61909979 61910398 0.283317249 0.065328087 
chr1 63253431 63254413 0.090799505 0.029828429 
chr1 64061530 64062519 0.023274675 0.09603559 
chr1 65733701 65734201 0.297952055 -0.036724144 
chr1 94153416 94153898 0.641591964 0.012994303 
chr1 100112308 100112822 0.191059976 0.020861026 
chr1 100436169 100436245 0.045055579 0.053255223 
chr1 100713823 100714287 0.026114662 -0.043754768 
chr1 111214849 111215337 0.000830083 -0.174664378 
chr1 111218226 111218674 0.028609698 0.071486755 
chr1 114413127 114414067 8.28E-05 -0.140138463 
chr1 114414346 114414954 8.28E-05 -0.140138463 
chr1 114415254 114415607 8.28E-05 -0.140138463 
chr1 149983089 149983332 0.481806589 0.013695731 
chr1 150129607 150129911 0.011515715 -0.061527856 
chr1 151129480 151129904 2.58E-05 -0.203542029 
chr1 153517654 153517859 0.015459655 0.111432355 
chr1 154956736 154957297 0.063435358 -0.088485589 
chr1 160681478 160682169 0.037990596 -0.040921991 
chr1 161038641 161039032 4.80E-09 -0.264158562 
chr1 161475461 161475849 0.002652877 -0.16864877 
chr1 173174911 173176087 0.082438786 -0.056016855 
chr1 173449733 173449965 0.102115617 0.04274556 
chr1 182357927 182358329 0.068397296 0.062977644 
chr1 192544836 192545273 0.015727132 -0.133234131 
chr1 198607773 198610160 0.018214222 -0.100339811 
chr1 198651498 198651957 0.407309588 -0.037295152 
chr1 199010586 199011304 0.176595525 -0.042360171 
chr1 199660947 199661166 0.163636918 -0.04654987 
chr1 211847053 211847783 0.01220632 0.100825287 
chr1 212115502 212117111 0.205896102 0.032334064 
chr1 220653057 220653280 0.173358467 0.062705846 
chr1 220864886 220865396 0.191583115 -0.055482328 
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chr1 221909048 221909616 0.107649879 -0.033404002 
chr1 230249386 230249800 0.067540877 -0.041459111 
chr1 236144282 236144424 0.428590605 -0.012324001 
chr1 241800452 241800722 0.004056696 -0.109795008 
chr1 248021785 248022041 0.200965059 -0.040951299 
chr2 10093863 10094145 0.149489146 -0.059018061 
chr2 16084776 16085714 0.026462974 -0.037242163 
chr2 21151188 21151541 0.006293461 -0.043007646 
chr2 25668139 25668364 0.117496348 -0.099659161 
chr2 38669779 38670055 0.192013286 0.04128462 
chr2 44308569 44309760 0.183046934 0.088509005 
chr2 45911195 45911602 0.277667197 -0.043119313 
chr2 46795289 46796098 0.022247323 -0.09536594 
chr2 47216781 47216960 0.001719588 0.178933354 
chr2 62426656 62427018 0.021726827 -0.05800806 
chr2 63270337 63271211 0.105911246 0.032484673 
chr2 67625367 67625994 0.014192426 -0.159468397 
chr2 68592241 68593052 0.000417575 -0.116575262 
chr2 68961351 68961704 0.000287308 -0.169520485 
chr2 68962521 68963097 0.000287308 -0.169520485 
chr2 70211010 70211141 0.074793806 -0.040295727 
chr2 80531572 80531693 0.01267564 -0.12761776 
chr2 100758499 100758785 0.037745155 -0.103856175 
chr2 120128320 120128605 0.096817539 0.042198961 
chr2 120279902 120280158 0.049402728 -0.060074519 
chr2 136870431 136870714 0.025691591 -0.101355347 
chr2 145418645 145418943 0.013432772 -0.148539776 
chr2 158298920 158300293 0.003845787 -0.126579923 
chr2 158300943 158301783 0.003845787 -0.126579923 
chr2 158759827 158760594 0.345419057 -0.037080746 
chr2 177023147 177023471 0.00782395 -0.119911701 
chr2 234160922 234161606 0.408179201 0.018866827 
chr2 237078975 237079346 0.014302383 -0.228144487 
chr2 241721037 241721263 0.157313624 0.04528784 
chr6 1608907 1609124 0.02149946 -0.144758449 
chr6 6701849 6702647 0.138073502 -0.044960274 
chr6 8069397 8069892 0.230098757 0.03717546 
chr6 10557112 10557387 0.084712725 0.085695391 
chr6 20149392 20149620 0.357755126 -0.029006955 
chr6 26595986 26596063 0.001774016 0.091203913 
chr6 43488870 43489065 0.039655641 -0.063665591 
chr6 43977929 43978138 0.067770138 -0.049733177 
chr6 72001391 72001673 0.650063432 0.021514144 
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chr6 75913118 75913414 0.039964536 0.036258368 
chr6 79922240 79922533 0.031223875 0.101608036 
chr6 83774408 83774634 0.088148366 0.024298645 
chr6 90995934 90996135 0.31033621 -0.018624689 
chr6 106630448 106630669 0.032929012 -0.092864789 
chr6 108145178 108145438 0.0002544 -0.15054077 
chr6 109629070 109629701 0.07455092 -0.113810962 
chr6 121655554 121655699 0.214211871 -0.076381082 
chr6 122721624 122721938 0.782800905 -0.005988991 
chr6 135946165 135946429 0.150413734 -0.027839173 
chr6 136376869 136377151 0.138900626 0.033768848 
chr6 139692242 139692766 0.071358568 -0.05626553 
chr6 142683092 142683312 0.060847098 0.063670558 
chr6 154567738 154568040 0.054281324 -0.064447241 
chr6 163814936 163815662 0.005485027 0.144576733 
chr6 164542172 164542650 0.06111785 -0.049408781 
chr8 1715132 1715419 0.020312359 -0.055086638 
chr8 17529635 17529755 0.212448998 -0.045221446 
chr8 23184678 23184867 0.033107474 -0.028156664 
chr8 26429564 26429693 0.089238216 -0.060735815 
chr8 28226653 28226969 0.070140437 -0.097469136 
chr8 29191531 29191754 0.074664184 0.033243325 
chr8 30402021 30402307 0.059656602 0.066092099 
chr8 37384529 37384565 0.056355149 -0.074172948 
chr8 41907137 41907600 0.033951722 -0.049325479 
chr8 43152678 43152944 0.101774677 0.10468965 
chr8 48921440 48921670 0.549728625 0.045360426 
chr8 66701734 66702089 0.000239452 0.133829622 
chr8 70588403 70588535 0.03737239 -0.118897956 
chr8 72271032 72271813 0.006526032 0.055557647 
chr8 79577640 79577971 0.027335434 -0.120166491 
chr8 86377077 86377304 0.205873288 0.079580679 
chr8 110346195 110346407 0.005606233 -0.146137424 
chr8 124050010 124051132 0.016160863 -0.201700733 
chr8 125642847 125643100 0.053762046 0.044152252 
chr8 125671231 125671900 0.105146153 0.033045224 
chr8 126011014 126011422 0.018217776 0.088449027 
chr8 128941581 128942080 0.029892253 0.074853732 
chr8 130956680 130957583 0.006432972 0.083997065 
chr8 131457070 131457446 0.091831138 -0.05001441 
chr8 141173973 141174525 0.457540782 0.018224753 
chr8 144816484 144816861 0.026970252 -0.06895942 
chr10 1402817 1403101 0.008030471 -0.051764156 
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chr10 3895156 3895674 0.055394379 0.036857931 
chr10 5485881 5486200 0.081087469 -0.097455401 
chr10 5490224 5490845 0.149235639 0.058475426 
chr10 5708419 5708659 0.059598542 -0.04917547 
chr10 6190543 6191242 0.017146089 -0.073584795 
chr10 21571119 21571557 0.30595094 -0.036460642 
chr10 25305780 25305987 0.101278552 -0.053808868 
chr10 70884710 70884845 0.087081301 -0.069417137 
chr10 73300885 73301322 0.080482241 0.055621735 
chr10 82175262 82175938 0.130456278 0.059308364 
chr10 82180528 82180732 0.061117646 0.080669928 
chr10 82279570 82279941 0.013820019 -0.139269935 
chr10 91006627 91007328 0.074112974 -0.077302683 
chr10 97144444 97145224 0.027219413 0.07734614 
chr10 97517128 97517433 0.026474464 -0.077219508 
chr10 98416374 98417030 0.002273819 -0.160411722 
chr10 99160683 99160877 0.080496726 -0.057407697 
chr10 102109210 102109419 0.049406421 -0.040765323 
chr10 103245631 103246048 0.057694353 -0.085267828 
chr10 104632622 104633383 0.004186243 0.118357444 
chr10 105414950 105415243 0.000643737 0.11508831 
chr10 112839077 112839216 0.153991099 -0.061788635 
chr10 114760114 114760561 0.00035593 0.158699963 
chr10 114801196 114802025 0.001798348 0.127830599 
chr10 114833951 114834429 0.100312432 0.057000362 
chr10 115824088 115824893 0.272925161 -0.0481567 
chr10 117577292 117577586 0.162784849 0.055245791 
chr10 122610736 122611078 0.157144273 -0.045241863 
chr10 123920852 123920995 0.042701586 -0.050719844 
chr10 124135396 124135700 0.198129182 0.050715394 
chr10 128592925 128593141 0.055414321 -0.036175689 
chr10 129846102 129846548 0.006558867 -0.157671746 
chr10 132127617 132128103 0.259498246 0.021822295 
chr10 132897979 132898573 0.023710989 0.071039385 
chr10 133793796 133793957 0.032971233 0.105305104 
chr10 135072811 135073045 0.04716606 -0.118765257 
chr10 135349833 135351027 0.098711704 0.049678185 
chr12 1663136 1663829 0.043716238 -0.046192522 
chr12 6166239 6166263 0.248521563 0.043982022 
chr12 6469500 6469539 0.03543076 0.03100671 
chr12 7060921 7061200 0.000293744 -0.145500528 
chr12 7308164 7308415 0.035942937 -0.126870767 
chr12 8216915 8217820 0.114586135 -0.033344046 
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chr12 8275965 8276317 0.013803864 -0.124748032 
chr12 11812172 11812279 0.005150697 0.120887626 
chr12 14928365 14928608 0.115301893 -0.022948594 
chr12 14995468 14996149 0.047220256 0.076344607 
chr12 15111717 15112453 0.00956376 -0.100766318 
chr12 26392741 26393036 0.032865677 0.114081438 
chr12 40010029 40010986 0.045439035 -0.052089161 
chr12 50419685 50419898 0.067364544 -0.028632215 
chr12 53268780 53268925 0.417767017 -0.0228861 
chr12 53497808 53497996 0.059851859 0.04586622 
chr12 54686256 54686746 0.047686589 -0.052394071 
chr12 62658334 62658491 0.012820313 -0.080748795 
chr12 69140644 69140871 0.00294898 -0.05840808 
chr12 75874872 75875171 0.028932969 -0.079091903 
chr12 76662008 76662319 0.230407077 0.084261368 
chr12 94978299 94978583 0.117548072 -0.021978496 
chr12 95000081 95001986 0.004387317 0.116714272 
chr12 96813903 96814310 0.097873514 0.084093689 
chr12 100538575 100538610 0.2054361 0.045371194 
chr12 101673825 101674109 0.068941654 -0.057969332 
chr12 102093732 102095643 0.086619668 0.103113517 
chr12 102618254 102618882 0.004350063 0.115790802 
chr12 104363097 104363317 0.005057558 -0.136091463 
chr12 106621844 106621970 0.036423307 0.046232273 
chr12 107045994 107046229 0.452216789 0.039977643 
chr12 109194765 109194928 0.017916085 0.035229392 
chr12 109838899 109839351 0.495308113 0.036933183 
chr12 110436172 110436489 0.240157029 0.050905326 
chr12 115108903 115109193 0.039598932 -0.062105131 
chr12 115125816 115126012 0.00275724 -0.14756063 
chr12 115129093 115129959 0.00030568 -0.187331894 
chr12 117173023 117173043 0.095202773 -0.072915207 
chr12 117433133 117434138 0.047336201 -0.0429966 
chr12 118796639 118796981 0.030025023 -0.061604516 
chr12 122204046 122204675 0.013695007 -0.095305859 
chr12 124865362 124865831 0.102138472 0.049625685 
chr12 125333888 125334033 0.171709363 0.077782925 
chr12 125575960 125576193 0.115106488 0.074375332 
chr22 18298189 18298467 0.036134946 0.088448521 
chr22 24761416 24761463 0.344188283 0.014164191 
chr22 30278371 30278842 0.162418389 0.047787343 
chr22 36924935 36925290 0.033885498 -0.073884507 
chr22 38472613 38473870 0.03773117 -0.050802924 
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chr22 40858582 40860665 0.001384889 -0.125891594 
chr22 43555410 43557147 0.018177759 -0.050771113 
chr22 45561031 45561107 0.264933651 0.033646427 
chr22 50955702 50956285 0.069548977 0.071080994 
chr17 1220102 1220359 0.00498105 0.124949686 
chr17 7483300 7483645 0.004383267 -0.086940803 
chr17 8027102 8027420 0.039741912 -0.033411302 
chr17 8867824 8868379 0.128040105 -0.057670787 
chr17 9950908 9951126 0.208451228 -0.047643312 
chr17 26646057 26646266 0.009588159 -0.219201828 
chr17 29150010 29150903 0.064732777 -0.026243112 
chr17 29641021 29641319 0.137955415 -0.060964811 
chr17 34415897 34416118 0.001156209 -0.090858161 
chr17 34417557 34418034 0.001156209 -0.090858161 
chr17 35299693 35299863 0.353425615 0.019486541 
chr17 40142289 40142472 0.07140143 0.050557861 
chr17 45908521 45908890 0.158883651 0.046498288 
chr17 47819090 47819795 0.007399875 -0.102310745 
chr17 47863126 47864532 0.071136849 0.073246062 
chr17 48940751 48941296 0.06118011 0.085294662 
chr17 56124678 56125091 0.022776363 -0.076070557 
chr17 56355449 56355594 0.038596305 -0.060609612 
chr17 56490498 56491520 0.022309925 0.109264262 
chr17 62204776 62206576 0.076370686 -0.096781936 
chr17 63541217 63541473 0.020481163 -0.049730423 
chr17 64448688 64449382 0.14072088 -0.047904076 
chr17 66877696 66877766 0.122227015 -0.086695187 
chr17 73406576 73407600 0.110354272 -0.048225572 
chr17 73630171 73630823 0.006844407 -0.104660956 
chr17 76375529 76375618 0.160821825 0.071059014 
chr17 79419543 79420749 0.017498542 0.105982501 
chr17 80050393 80050984 0.035750412 -0.102212516 
chr17 80052124 80053059 0.00234477 0.110938993 
chr17 80416305 80416449 0.377968144 0.039260145 
chr5 10304741 10305342 0.016968763 -0.102322221 
chr5 32780268 32780484 0.043125176 -0.062892296 
chr5 34655547 34655935 0.04433336 0.097710785 
chr5 34687673 34687965 0.027202557 0.113639208 
chr5 36535659 36536198 0.188674087 -0.035795174 
chr5 55737286 55737497 0.016894229 0.094145368 
chr5 64333579 64333820 0.011515023 0.080503852 
chr5 66491448 66492361 0.010515394 -0.065840584 
chr5 67585536 67585875 0.027604432 0.069279842 
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chr5 74244430 74245271 0.051883314 -0.077775325 
chr5 77803248 77803367 0.014339375 -0.094089602 
chr5 79028795 79029354 0.404746582 -0.014708512 
chr5 106908226 106908482 0.040259849 0.089666375 
chr5 106938858 106939295 0.103233424 0.063036468 
chr5 108085570 108085868 0.014590337 -0.144368703 
chr5 133968325 133968612 0.19291661 0.155371226 
chr5 134787566 134787794 0.121578462 -0.04209435 
chr5 141670403 141670927 0.093448335 0.087272102 
chr5 148208221 148208626 0.005235308 -0.099159277 
chr5 149108648 149108898 0.070181892 0.0958248 
chr5 149464925 149465615 0.008300488 -0.087832678 
chr5 150726558 150727030 0.333779062 0.04041369 
chr5 169760638 169760900 1.42E-05 -0.194462311 
chr5 176325586 176326273 0.178871723 -0.050743362 
chr5 178803895 178804058 0.010600527 -0.111699146 
chr7 1408433 1408951 0.01030415 0.063819595 
chr7 8302335 8302647 0.852262755 0.008577271 
chr7 26460385 26460633 0.017227015 -0.112177321 
chr7 27201206 27201499 0.000244 -0.154545194 
chr7 27202553 27202993 0.00772616 -0.163900092 
chr7 27203073 27203466 0.00772616 -0.163900092 
chr7 30287772 30288094 0.502192871 0.028442713 
chr7 47672033 47673452 0.001650023 0.090694865 
chr7 50345715 50346835 0.000203584 -0.123971624 
chr7 73624879 73625346 0.025835427 -0.095097771 
chr7 75549990 75550275 0.240896483 -0.019749676 
chr7 75957929 75958231 0.014476618 -0.079952002 
chr7 76828348 76828576 0.032838026 -0.069069628 
chr7 97500452 97501026 0.05303718 0.096679458 
chr7 100238885 100239167 0.074148968 0.074548168 
chr7 105318767 105318983 0.001087181 0.126246501 
chr7 106704715 106705240 0.001244862 0.088189068 
chr7 107609751 107610536 0.256006703 0.064722568 
chr7 107692799 107693160 0.020384645 -0.090978916 
chr7 127857315 127858302 0.193642885 0.043408718 
chr7 127889822 127890030 0.177358186 0.052936735 
chr7 130622635 130623162 0.062198878 0.062047453 
chr7 131241745 131242050 0.099786111 -0.055238515 
chr7 139529064 139530436 7.05E-05 -0.203984492 
chr7 140048085 140048549 0.219770505 0.023951494 
chr7 151039508 151039684 0.00124038 0.194317077 
chr14 20898926 20899114 0.001031265 -0.133171333 
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chr14 21568858 21569390 0.227490337 0.046680964 
chr14 23788798 23789618 0.113051505 -0.098799804 
chr14 31888216 31888303 0.051428286 -0.077015105 
chr14 39737165 39737329 0.09171178 0.047880934 
chr14 55833724 55834573 0.128314832 0.019852413 
chr14 55834889 55835484 0.128314832 0.019852413 
chr14 74961318 74961491 0.02971491 -0.068992065 
chr14 75361059 75361571 0.002412449 -0.165986778 
chr14 77791405 77791671 0.010968896 0.134177876 
chr14 81867674 81868031 0.081282534 -0.073907314 
chr14 89707672 89708616 0.005943992 0.082570716 
chr14 93117257 93117768 0.003786645 -0.112199089 
chr14 97180040 97180391 0.161683822 0.025082244 
chr14 100531888 100532636 0.003391464 -0.113839928 
chr9 14203697 14204081 0.001304379 0.122130904 
chr9 32457089 32457364 0.019332685 0.140039676 
chr9 36778847 36778989 0.017411606 -0.117459817 
chr9 93565879 93566460 0.007420128 0.094453504 
chr9 95726604 95726801 0.000782954 -0.190154032 
chr9 113021805 113022191 0.153227162 0.059319005 
chr9 113310163 113310641 0.635801168 -0.026481336 
chr9 114424532 114424918 0.008616226 -0.054665936 
chr9 116379329 116379646 0.034041424 0.053038017 
chr9 117085126 117085447 0.089241078 0.033000789 
chr9 117147509 117147976 0.090278173 0.057770456 
chr9 117692618 117692950 0.000933629 -0.161745875 
chr9 130281483 130281851 0.121434378 -0.03946649 
chr9 131369913 131370522 0.021422761 0.053623327 
chr9 132804046 132804253 0.060174876 -0.083590765 
chr13 29293918 29294030 0.234074293 0.075604237 
chr13 32780792 32781098 0.477862977 0.019990114 
chr13 36049213 36050887 0.000513404 -0.083527653 
chr13 40809925 40810619 0.449595212 0.027281116 
chr13 40943529 40943850 0.045248093 0.073827692 
chr13 44936911 44937231 0.071609449 -0.039506342 
chr13 45564095 45564224 0.004529161 -0.179434382 
chr13 45694501 45694858 0.004084029 -0.071848765 
chr13 46751279 46752608 0.014544051 -0.091356551 
chr13 46753288 46754147 0.014544051 -0.091356551 
chr13 49683338 49683473 0.149221767 0.029842321 
chr13 50204794 50205145 0.044279538 -0.107739618 
chr13 114018968 114019138 0.229393431 -0.053562829 
chr3 9911613 9911971 0.014015847 0.066336204 
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chr3 15667550 15667785 0.057143936 -0.043614963 
chr3 15681784 15682347 0.152744834 -0.05127628 
chr3 24869934 24870287 0.029777881 0.046387087 
chr3 32412954 32413251 0.172866571 0.03624256 
chr3 37907270 37907753 0.374453931 0.023449625 
chr3 38007994 38008396 0.031627285 -0.085747522 
chr3 40499457 40499546 0.026209488 0.061704304 
chr3 46036856 46037289 0.013540094 -0.234110654 
chr3 52445047 52445468 0.164356522 0.045244721 
chr3 52567262 52567405 0.130156467 -0.037378327 
chr3 57262305 57262906 0.239989212 -0.051311872 
chr3 65434405 65434559 0.049562076 -0.048552937 
chr3 66633695 66634011 0.087614339 -0.038846936 
chr3 67049442 67049635 0.159046189 0.057621246 
chr3 72870608 72870903 0.026213972 -0.070105607 
chr3 72896699 72897027 0.004251486 -0.192497184 
chr3 112692217 112693342 0.009566716 -0.067486844 
chr3 112964544 112965111 0.026237876 0.087180801 
chr3 124349805 124350028 0.053370691 -0.053070703 
chr3 124511021 124511255 0.112577227 0.052593515 
chr3 124511634 124511961 0.112577227 0.052593515 
chr3 124559262 124559467 0.33380135 0.051607354 
chr3 127512341 127512749 0.300572926 0.046883681 
chr3 133615194 133615551 0.012336117 0.053271596 
chr3 138311777 138311800 0.091346454 0.055603918 
chr3 141108490 141109631 0.01672593 -0.121198507 
chr3 150322081 150322440 0.000503571 -0.14397228 
chr3 150965754 150966036 0.115599 -0.047542803 
chr3 151102250 151102484 0.314598291 0.057538343 
chr3 157325748 157326168 0.000152002 -0.188356272 
chr3 159706955 159707276 0.510455058 -0.037543221 
chr3 169897652 169897802 0.06071042 -0.081619325 
chr3 170894740 170894972 0.246755268 0.062234751 
chr3 185226120 185226426 0.11891308 -0.025769524 
chr3 186500542 186500813 0.057501757 0.053855992 
chr3 187437450 187437801 0.183180484 -0.023522408 
chr3 188585553 188586208 0.255225767 0.039438945 
chr3 196063662 196064900 0.200280698 -0.077940287 
chr3 196304666 196305922 0.051206131 0.032303493 
chr16 16123803 16124667 0.028137766 0.062463282 
chr16 20909935 20910137 0.085974868 0.056191121 
chr16 30455438 30455975 0.03253984 -0.0577708 
chr16 46957730 46958679 0.031950761 -0.034656493 
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chr16 50059655 50059880 0.063328638 -0.103644757 
chr16 50715116 50715299 0.000204672 -0.169680371 
chr16 55540360 55540833 0.012314177 -0.055940936 
chr16 56137894 56138256 0.004769343 0.066758804 
chr16 57278607 57278995 0.317131448 0.045084544 
chr16 69457347 69457490 0.01244399 0.086794906 
chr16 79370715 79370926 0.118336141 0.035616683 
chr16 83549673 83549934 0.092723296 0.034427003 
chr16 85376056 85376680 0.182709459 -0.023703324 
chr16 87903345 87904117 0.034324129 -0.089302202 
chr16 88770501 88770848 0.043240371 -0.073898435 
chr21 16057979 16058284 0.414561669 -0.033457948 
chr21 33689979 33690246 0.149919203 -0.039646958 
chr21 35448249 35449067 0.003752114 -0.121181521 
chr21 36398548 36398828 0.000151796 -0.15178274 
chr21 36420456 36421805 4.31E-06 -0.279855942 
chr21 37412563 37413036 0.057139401 0.073919244 
chr21 39868683 39869555 0.000107641 -0.134357154 
chr21 40776034 40777497 0.304302694 0.020796314 
chr18 2960647 2960946 0.226393124 0.074511207 
chr18 10457031 10457507 0.093670381 0.042061125 
chr18 46277273 46277494 0.060855394 0.080607141 
chr18 56809110 56809370 0.047576474 -0.102872363 
chr18 77440474 77440960 0.124164823 -0.03050826 
chr19 7733678 7734230 0.017884245 -0.067224475 
chr19 12920962 12921262 0.070335289 -0.037572965 
chr19 15574480 15574831 0.019917347 -0.119050573 
chr19 17669572 17669647 0.503151826 -0.027583264 
chr19 18508116 18508457 0.155971856 -0.0272848 
chr19 18682314 18682390 0.137872609 0.056746254 
chr19 40750567 40750963 0.00536166 0.105072993 
chr19 42830523 42830820 0.017467435 -0.125098373 
chr19 42912089 42912557 0.063280265 -0.066215746 
chr19 45225646 45225969 0.096953319 0.111422729 
chr19 49841249 49841895 0.027967301 0.091393575 
chr19 51645546 51714605 0.026484673 -0.072463543 
chr19 54876429 54876765 0.026489679 -0.097348731 
chr11 6267881 6268720 0.001427368 0.142949402 
chr11 10316893 10317243 0.015285684 -0.079842283 
chr11 10324978 10325218 0.006833463 -0.076195352 
chr11 13359375 13359540 0.287397995 0.033110364 
chr11 14563296 14563419 0.268961707 0.042292388 
chr11 18127092 18127637 0.22057406 0.022446951 
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chr11 27490752 27491523 0.020887869 -0.168418694 
chr11 32852321 32852814 0.181458128 0.058426216 
chr11 47291136 47291346 0.117725556 -0.06055027 
chr11 47415025 47415403 0.005612808 -0.09283909 
chr11 57067776 57068975 0.031735717 -0.108159774 
chr11 63528336 63528808 0.009374816 0.075120856 
chr11 64544695 64545147 0.074007346 0.080573957 
chr11 66673568 66673798 0.049344564 0.089939048 
chr11 67036383 67036711 0.000861836 -0.127008445 
chr11 67165584 67166226 0.038535186 0.032864959 
chr11 73692113 73692198 0.048032778 -0.086506376 
chr11 76337568 76338271 0.052017168 -0.077393197 
chr11 117858523 117858767 0.000608402 -0.109964715 
chr11 120987491 120987707 0.070233309 -0.032303992 
chr11 122849412 122849982 0.034711309 0.095100232 
chr15 37173455 37174113 0.028601312 -0.075724131 
chr15 52404555 52404986 0.115604037 0.071796217 
chr15 52820075 52820295 0.694329386 0.024475175 
chr15 61136559 61136807 0.001200488 -0.123028637 
chr15 62343394 62344034 0.214289764 -0.064912798 
chr15 63571085 63571484 0.284299059 -0.051881135 
chr15 69426262 69426542 0.018055549 -0.112554107 
chr15 69708054 69708318 0.020715438 0.049924329 
chr15 77478505 77479038 0.231666602 0.070100851 
chr15 79471213 79471368 0.074622439 -0.035916955 
chr15 89977287 89977470 0.00877423 -0.073352554 
chr15 90701174 90701775 0.085843566 0.0589646 
chr15 96902600 96903113 4.02E-05 -0.13012121 
chr15 96905568 96906197 0.000917372 -0.151366539 
chr15 96907528 96907914 0.000917372 -0.151366539 
chr20 1879865 1880324 0.001414611 0.163898814 
chr20 3527981 3528426 0.147326039 0.084492638 
chr20 3746584 3746692 0.139490039 -0.044307576 
chr20 18269464 18269677 0.004138053 0.11442861 
chr20 25033629 25034262 0.035246291 0.053724766 
chr20 25251494 25252151 0.00912653 0.050518875 
chr20 30258398 30258882 0.062783463 0.088332976 
chr20 33466246 33466396 0.135099492 0.049631059 
chr20 35233479 35233726 0.178100009 -0.054084787 
chr20 36104587 36105045 0.155524754 -0.044843164 
chr20 36823215 36823538 0.060042606 -0.026596859 
chr20 39314354 39315324 0.016335516 -0.073400089 
chr20 43953416 43953593 0.222068845 -0.027653814 
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chr20 47803610 47804113 0.04857818 -0.099555153 
chr20 47839439 47839685 0.156286748 -0.02991861 
chr20 48924232 48924768 0.004243497 0.096121482 
chr20 56135219 56135721 0.008351783 0.073282322 
chr20 56135935 56137320 0.003187762 0.087199606 
chr20 56138648 56138937 0.003187762 0.087199606 
chr20 56139464 56139982 0.003187762 0.087199606 
chr20 58512538 58512948 0.099138641 0.056386238 
chr4 3295253 3295496 0.21813933 0.078202348 
chr4 38858508 38859749 0.003242039 -0.125613648 
chr4 39408228 39410160 0.044594542 -0.072267154 
chr4 84034389 84034401 0.000415556 -0.184889567 
chr4 86398976 86399113 0.063282407 0.060784671 
chr4 87672032 87672388 0.100709592 -0.079778073 
chr4 108552737 108553088 0.052559898 -0.072581024 
chr4 108928564 108928770 0.04453389 0.055177969 
chr4 113861384 113862156 0.027308541 -0.078932185 
chr4 119855498 119855703 0.1507209 0.081634037 
chr4 120547931 120548111 0.051707622 0.108026119 
chr4 129162516 129162816 0.046803004 -0.037213593 
chr4 129230121 129231987 0.145876681 0.034008826 
chr4 184241311 184241863 0.04719212 0.079883969 
chr4 184774713 184775223 0.010583934 0.096433022 
chr4 185303774 185304147 0.044240008 -0.068515138 
chr4 185741474 185741616 0.21397322 0.051362717 
chr4 185743539 185744674 0.207983162 -0.070745646 
chr4 185796824 185797589 0.174978393 0.035307295 
 
Table 7. Conserved mouse-human DMRs. This table lists the 497 mouse DMRs mappable onto the 
human chromosome and with 5kb of a human probe.  Listed are the genomic coordinates and width for 
each mouse differentially methylated region (DMR), q-values for the mouse DMRs derived from false 
discovery rate (see methods, qval), the gene symbol nearest gene to the mouse DMR, the p-values for 
the corresponding changes in human obesity and surgery, and the slopes for the methylation change for 





Table 8. Enrichment of cross-species DMRs over DIAGRAM GWAS loci 
DIAGRAM 
Number of GWAS loci 
overlapping conserved 
DMRs 
Number of GWAS loci 
overlapping conserved, 
same direction DMRs 
Cutoff # Loci Adipose Islet Adipose Islet 
p<5e-08 18 2 (0.017) 0 (0.292) 1 (0.0113) 0 (0.108) 
p<1e-07 20 2 (0.025) 0 (0.329) 1 (0.0154) 0 (0.121) 
p<1e-06 35 3 (0.016) 1 (0.119) 1 (0.0376) 0 (0.179) 
p<1e-05 215 6 (0.005) 2 (0.119) 2 (0.0253) 1 (0.058) 
p<1e-04 428 9 (0.209) 5 (0.239) 3 (0.192) 2 (0.166) 
p<1e-03 1601 24 (0.48) 12 (0.600) 6 (0.597)  7 (0.086) 
p<1e-02 8353 77 (0.336) 39 (0.560) 27 (0.119) 12 (0.573) 
 
Table 8. Enrichment of cross-species DMRs over DIAGRAM GWAS loci. This table summarizes the 
number and significance of overlaps of cross-species conserved adipose and pancreatic islet loci with 
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Known cytokine; important role in 
development of Type 1 Diabetes in mice 












inside intron 337 
 
+ 




inside intron 20427 
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0.00049 Central component in insulin-signaling pathway (Cho et al., 2001) 











overlaps 5' 0 
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exon 146 + 0.0015 
Putative mouse transcript; overlaps with 











inside intron 11100 + 0.002 
Differentially expressed in animal models 





















































promoter 453 + 0.0072 
Central component in de novo lipogenesis 





overlaps 5' 0 + 0.0072 
Central component in de novo lipogenesis 















overlaps 5' 0 = 0.0087 
Significantly decreased expression in 






exon(s) 157 + 0.0099  
BLUE – Genes previously found by conventional GWAS as being associated with T2D after multiple 
testing correction. RED – Genes near conserved, cross-species epigenetic changes that overlap LD blocks 
where genetic variants have an individually significant association with T2D. Shown are the names of the 
nearest gene to the mouse and human differential methylation, the position of the DMR relative to the 
gene (only one DMR is outside the gene), the distance to the transcriptional start site (TSS), whether the 
direction of methylation change (sign of smoothed effect statistic) post-RYGB surgery reverts toward 





Table 10. Cross-species, directionally consistent pancreatic islet DMRs that overlap with DIAGRAM 












chr3 97536603 97536878 276 0.093610895 
chr1 147083046 147084059 1014 0.079418323 
chr2 169757423 169758143 721 0.08021799 
chr11 17405939 17406583 645 0.080153144 
chr11 17406741 17407082 342 0.077431401 
chr11 17407373 17408268 896 0.081308921 
chr11 27491277 27491838 562 -0.078049539 
chr14 77511555 77511688 134 -0.081407373 
chr12 39297915 39298205 291 -0.071278015 
chr5 123149655 123150023 369 0.073113986 
 
pval qval fwer nearestGene nearestGeneDesc nearestGeneDist 
0.0015625 0.012831439 0.018 Arl6 downstream 34177 
6.51E-05 0.002027957 0 Bcl9 overlaps 5' 0 
6.51E-05 0.002027957 0 G6pc2 overlaps 5' 0 
0.001497396 0.012831439 0.017 Kcnj11 downstream 3320 
0.002929688 0.017074093 0.033 Kcnj11 overlaps 3' 2900 
6.51E-05 0.002027957 0 Kcnj11 inside 1740 
0.000911458 0.010692866 0.011 Lgr4 inside 2417 
0.016080729 0.045394558 0.123 6430527G18Rik upstream 15082 
0.004231771 0.020119472 0.044 Cpne8 inside 926 








0.018109593 0.00069 rs17302349 
0.018785468 0.00042 rs7512513 
0.005552449 0.0034 rs16856159 
0.011107651 4.40E-06 rs5215 
0.011107651 4.40E-06 rs5215 
0.001281212 4.40E-06 rs5215 
0.045056138 0.0077 rs7945211 
0.024935476 0.0029 rs17752640 
0.008167247 1.60E-05 rs10506132 
0.010390504 0.00051 rs7708937 
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Table 10. Cross-species, directionally consistent DMRs that overlap with DIAGRAM T2D GWAS loci. 
Similar to Table 3, this table lists pancreatic islet DMRs that are significant across species, directionally 





Table 11. Overlap of conserved and directionally consistent adipose DMRs and adipose enhancers 
chr start end Mouse_Nearest_Gene distToNearestAdiposeEnhancer coordsOfNearestAdiposeEnhancer 
chr1 19804495 19805076 Capzb 0 chr1:19739675-19833107 
chr1 48351513 48351750 OTTMUSG00000008561 -546242 chr1:47798033-47805271 
chr1 64061530 64062519 Pgm2 0 chr1:64055024-64092549 
chr1 111214849 1.11E+08 Kcna3 199363 chr1:111414700-111418046 
chr1 114413127 1.14E+08 Ptpn22 -13238 chr1:114398212-114399889 
chr1 114414346 1.14E+08 Ptpn22 -14457 chr1:114398212-114399889 
chr1 114415254 1.14E+08 Ptpn22 -15365 chr1:114398212-114399889 
chr1 150129607 1.5E+08 Plekho1 0 chr1:150113475-150160132 
chr1 151129480 1.51E+08 Tnfaip8l2 -10710 chr1:151103285-151118770 
chr1 160681478 1.61E+08 Cd48 -131593 chr1:160543677-160549885 
chr1 161038641 1.61E+08 Arhgap30 0 chr1:161037436-161039509 
chr1 161475461 1.61E+08 Fcgr3 23356 chr1:161499205-161533394 
chr1 192544836 1.93E+08 Rgs1 -14758 chr1:192528534-192530078 
chr1 198607773 1.99E+08 Ptprc 16327 chr1:198626487-198627845 
chr1 211847053 2.12E+08 Nek2 -55976 chr1:211784613-211791077 
chr2 16084776 16085714 Mycn -238915 chr2:15843316-15845861 
chr2 47216781 47216960 Ttc7 0 chr2:47166289-47314830 
chr2 62426656 62427018 B3gnt2 -588 chr2:62421832-62426068 
chr2 67625367 67625994 Etaa1 -136215 chr2:67486284-67489152 
chr2 68592241 68593052 Plek 0 chr2:68592492-68596426 
chr2 68961351 68961704 Arhgap25 28829 chr2:68990533-69007401 
chr2 68962521 68963097 Arhgap25 27436 chr2:68990533-69007401 
chr2 100758499 1.01E+08 Lonrf2 49822 chr2:100808607-100816096 
chr2 145418645 1.45E+08 Zeb2 0 chr2:145417385-145430018 
chr2 158298920 1.58E+08 Pscdbp 53777 chr2:158354070-158355373 
chr2 158300943 1.58E+08 Pscdbp 52287 chr2:158354070-158355373 
chr2 177023147 1.77E+08 Hoxd3 -17061 chr2:176992872-177006086 
chr6 1608907 1609124 Foxc1 2698 chr6:1611822-1614843 
chr6 26595986 26596063 Abt1 -22946 chr6:26571587-26573040 
chr6 75913118 75913414 Col12a1 0 chr6:75909506-75944578 
chr6 79922240 79922533 Hmgn3 19305 chr6:79941838-79944997 
chr6 108145178 1.08E+08 Scml4 128176 chr6:108273614-108279958 
chr6 163814936 1.64E+08 Qk 0 chr6:163812425-163859943 
chr8 1715132 1715419 Cln8 0 chr8:1693029-1737972 
chr8 41907137 41907600 Myst3 0 chr8:41890037-41909112 
chr8 66701734 66702089 Pde7a 50510 chr8:66752599-66755870 
chr8 70588403 70588535 Slco5a1 -70101 chr8:70516915-70518302 
chr8 79577640 79577971 3110050N22Rik -49109 chr8:79527654-79528531 
chr8 128941581 1.29E+08 Myc -1615 chr8:128938286-128939966 
chr8 130956680 1.31E+08 0910001A06Rik 0 chr8:130944190-131028814 
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chr8 144816484 1.45E+08 AA409316 -100509 chr8:144714373-144715975 
chr10 6190543 6191242 Rbm17 0 chr10:6182494-6261722 
chr10 97144444 97145224 Sorbs1 0 chr10:97067610-97208276 
chr10 97517128 97517433 Entpd1 -14493 chr10:97501217-97502635 
chr10 98416374 98417030 Pik3ap1 15807 chr10:98432837-98434307 
chr10 104632622 1.05E+08 As3mt -53262 chr10:104497945-104579360 
chr10 105414950 1.05E+08 Sh3pxd2a 0 chr10:105396542-105439328 
chr10 114760114 1.15E+08 Tcf7l2 0 chr10:114708122-114899787 
chr10 114801196 1.15E+08 Tcf7l2 0 chr10:114708122-114899787 
chr10 129846102 1.3E+08 Ptpre 0 chr10:129845340-129863251 
chr10 133793796 1.34E+08 Bnip3 0 chr10:133785164-133796990 
chr10 135072811 1.35E+08 6430531B16Rik 0 chr10:135072055-135075460 
chr12 1663136 1663829 Wnt5b 21029 chr12:1684858-1721862 
chr12 7060921 7061200 Ptpn6 501 chr12:7061701-7063206 
chr12 8275965 8276317 Clec4a4 32585 chr12:8308902-8310793 
chr12 15111717 15112453 Arhgdib 0 chr12:15101053-15116243 
chr12 26392741 26393036 Sspn 0 chr12:26391495-26392980 
chr12 62658334 62658491 Usp15 272793 chr12:62931284-62932711 
chr12 69140644 69140871 Slc35e3 -62479 chr12:69058087-69078165 
chr12 75874872 75875171 Glipr1 0 chr12:75873225-75877983 
chr12 95000081 95001986 Tmcc3 6592 chr12:95008578-95017711 
chr12 102618254 1.03E+08 Pmch -49193 chr12:102565262-102569061 
chr12 104363097 1.04E+08 Tdg -1480 chr12:104357862-104361617 
chr12 115108903 1.15E+08 Tbx3 0 chr12:115106745-115123443 
chr12 115125816 1.15E+08 Tbx3 -2373 chr12:115106745-115123443 
chr12 115129093 1.15E+08 Tbx3 -5650 chr12:115106745-115123443 
chr12 118796639 1.19E+08 Taok3 0 chr12:118794373-118796651 
chr22 40858582 40860665 Mkl1 -17872 chr22:40839368-40840710 
chr17 1220102 1220359 Tusc5 0 chr17:1170362-1234434 
chr17 7483300 7483645 Cd68 0 chr17:7474748-7488471 
chr17 8027102 8027420 Hes7 2176 chr17:8029596-8030860 
chr17 34415897 34416118 Ccl3 -114527 chr17:34299542-34301370 
chr17 34417557 34418034 Ccl3 -116187 chr17:34299542-34301370 
chr17 47819090 47819795 5730593F17Rik 0 chr17:47806578-47820892 
chr17 56355449 56355594 Mpo 57556 chr17:56413150-56417783 
chr17 79419543 79420749 Bahcc1 13038 chr17:79433787-79439686 
chr17 80052124 80053059 Fasn 862 chr17:80053921-80071409 
chr5 34655547 34655935 Rai14 301318 chr5:34957253-34958750 
chr5 34687673 34687965 Rai14 269288 chr5:34957253-34958750 
chr5 66491448 66492361 Cd180 -981 chr5:66488909-66490467 
chr5 67585536 67585875 Pik3r1 0 chr5:67509819-67590624 
chr5 77803248 77803367 Lhfpl2 0 chr5:77799632-77874486 
chr5 106908226 1.07E+08 Efna5 0 chr5:106905355-106931655 
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chr5 108085570 1.08E+08 Fert2 0 chr5:108082660-108086010 
chr5 148208221 1.48E+08 Adrb2 0 chr5:148204240-148255435 
chr5 149464925 1.49E+08 Csf1r 25190 chr5:149490805-149493891 
chr5 169760638 1.7E+08 Kcnmb1 -564 chr5:169756410-169760074 
chr5 178803895 1.79E+08 Adamts2 -49139 chr5:178691630-178754756 
chr7 1408433 1408951 Micall2 89119 chr7:1498070-1502021 
chr7 26460385 26460633 Snx10 -20840 chr7:26437305-26439545 
chr7 27201206 27201499 Hoxa9 0 chr7:27199735-27220891 
chr7 27202553 27202993 Hoxa9 0 chr7:27199735-27220891 
chr7 27203073 27203466 Hoxa9 0 chr7:27199735-27220891 
chr7 50345715 50346835 Ikzf1 -235589 chr7:50107911-50110126 
chr7 73624879 73625346 Lat2 -14413 chr7:73587401-73610466 
chr7 76828348 76828576 Fgl2 16610 chr7:76845186-76846431 
chr7 106704715 1.07E+08 Prkar2b 0 chr7:106618925-106721216 
chr7 139529064 1.4E+08 Tbxas1 -51336 chr7:139471181-139477728 
chr14 75361059 75361571 Dlst -1825 chr14:75347589-75359234 
chr14 77791405 77791671 Gstz1 -8940 chr14:77772242-77782465 
chr14 89707672 89708616 Foxn3 -13657 chr14:89686978-89694015 
chr14 93117257 93117768 Rin3 -63158 chr14:93052381-93054099 
chr14 100531888 1.01E+08 Evl 9386 chr14:100542022-100544258 
chr9 14203697 14204081 Nfib 0 chr9:14132520-14325750 
chr9 32457089 32457364 Ddx58 -76 chr9:32383078-32457013 
chr9 95726604 95726801 Fgd3 -25224 chr9:95690523-95701380 
chr9 114424532 1.14E+08 Gng10 0 chr9:114409522-114425974 
chr9 116379329 1.16E+08 Rgs3 0 chr9:116348945-116398471 
chr9 117692618 1.18E+08 Tnfsf8 0 chr9:117690537-117702171 
chr9 131369913 1.31E+08 Spna2 0 chr9:131369112-131371185 
chr13 36049213 36050887 Mab21l1 0 chr13:36044089-36051808 
chr13 40943529 40943850 Foxo1 0 chr13:40940889-40958355 
chr13 46751279 46752608 Lcp1 -5166 chr13:46743863-46746113 
chr13 46753288 46754147 Lcp1 -7175 chr13:46743863-46746113 
chr13 50204794 50205145 Arl11 -4181 chr13:50189809-50200613 
chr3 9911613 9911971 Cidec 0 chr3:9902655-9941408 
chr3 24869934 24870287 Rarb -186244 chr3:24680201-24683690 
chr3 112692217 1.13E+08 Cd200r1 42134 chr3:112735476-112739663 
chr3 112964544 1.13E+08 Boc 339 chr3:112965450-112966583 
chr3 150322081 1.5E+08 2810407C02Rik 0 chr3:150320270-150323270 
chr3 157325748 1.57E+08 Veph1 -33016 chr3:157290209-157292732 
chr16 16123803 16124667 Abcc1 0 chr16:16107968-16124361 
chr16 50715116 50715299 9130017C17Rik 13526 chr16:50728825-50732873 
chr16 55540360 55540833 Mmp2 -17985 chr16:55504207-55522375 
chr16 56137894 56138256 Gnao1 -266909 chr16:55869127-55870985 
chr16 69457347 69457490 Cyb5b -5180 chr16:69417593-69452167 
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chr16 87903345 87904117 BC048644 47037 chr16:87951154-87953835 
chr16 88770501 88770848 Rnf166 0 chr16:88766514-88770583 
chr21 36398548 36398828 Runx1 20276 chr21:36419104-36424477 
chr21 36420456 36421805 Runx1 0 chr21:36419104-36424477 
chr21 39868683 39869555 Erg 0 chr21:39830852-39877989 
chr18 56809110 56809370 Sec11c -86050 chr18:56708840-56723060 
chr19 15574480 15574831 A430107D22Rik -10634 chr19:15562049-15563846 
chr19 40750567 40750963 Akt2 0 chr19:40734674-40793531 
chr19 49841249 49841895 Cd37 493 chr19:49842388-49845001 
chr19 51645546 51714605 Cd33 -3881 chr19:51631167-51641665 
chr19 54876429 54876765 Lair1 0 chr19:54870067-54886694 
chr11 6267881 6268720 Cnga4 -19648 chr11:6239734-6248233 
chr11 10316893 10317243 Adm 0 chr11:10312838-10351582 
chr11 10324978 10325218 Adm 0 chr11:10312838-10351582 
chr11 47415025 47415403 Sfpi1 0 chr11:47412747-47423042 
chr11 63528336 63528808 2700081O15Rik 5253 chr11:63534061-63538555 
chr11 66673568 66673798 Pcx 0 chr11:66641441-66703669 
chr11 67036383 67036711 Adrbk1 0 chr11:67029927-67057696 
chr11 67165584 67166226 Ppp1ca -23002 chr11:67138749-67142582 
chr11 73692113 73692198 Ucp2 -2531 chr11:73687719-73689582 
chr11 117858523 1.18E+08 Il10ra 0 chr11:117857980-117859426 
chr11 122849412 1.23E+08 Bsx -44045 chr11:122803497-122805367 
chr15 37173455 37174113 Meis2 210804 chr15:37384917-37395168 
chr15 61136559 61136807 Rora -42316 chr15:61091049-61094243 
chr15 96902600 96903113 Nr2f2 -1250 chr15:96867016-96901350 
chr15 96905568 96906197 Nr2f2 -4218 chr15:96867016-96901350 
chr15 96907528 96907914 Nr2f2 -6178 chr15:96867016-96901350 
chr20 18269464 18269677 6330439K17Rik 31641 chr20:18301318-18303522 
chr20 25033629 25034262 Acss1 0 chr20:25013038-25040024 
chr20 25251494 25252151 Pygb 831 chr20:25252982-25254488 
chr20 39314354 39315324 Mafb 0 chr20:39309302-39319699 
chr20 47803610 47804113 Stau1 0 chr20:47801190-47805535 
chr20 48924232 48924768 Cebpb 0 chr20:48860807-48930471 
chr20 56135219 56135721 Pck1 0 chr20:56118475-56165809 
chr20 56135935 56137320 Pck1 0 chr20:56118475-56165809 
chr20 56138648 56138937 Pck1 0 chr20:56118475-56165809 
chr20 56139464 56139982 Pck1 0 chr20:56118475-56165809 
chr4 38858508 38859749 Tlr6 0 chr4:38857521-38860641 
chr4 84034389 84034401 Plac8 -99147 chr4:83930601-83935242 
chr4 108928564 1.09E+08 Hadh 0 chr4:108897305-108937926 
chr4 113861384 1.14E+08 Larp7 -15696 chr4:113844242-113845688 
chr4 184241311 1.84E+08 Cldn22 75490 chr4:184317353-184318852 
chr4 184774713 1.85E+08 Stox2 -21381 chr4:184749297-184753332 
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chr4 185303774 1.85E+08 Irf2 0 chr4:185302924-185340443 
 
Table 11. Overlapping methylation change and adipose enhancer regions. This table displays the 171 
cross-species conserved and directionally consistent regions with differential methylation along with the 






Table 12. Human Subject Information 
 




BMI Waist circumference 
(cm) 
Ob T2D 42 37.00 118 
Ob T2D 62 36.00 143 
Ob ND 43 40.30 137 
Ob T2D 56 37.10 124 
Ob ND 36 41.60 125 
Ob T2D 52 42.90 140 
Ob ND 49 40.00 140 
Ob T2D 41 40.40 125 
Ob ND 50 35.60 122 
Ob T2D 34 40.30 139 
Ob T2D 37 42.70 139 
Ob T2D 36 45.84 143 
Ob ND 41 37.22 122 
Ob ND 59 37.24 120 
L ND 39 24.50 87 
L ND 41 27.80 89 
L ND 59 25.10 100 
L ND 36 26.30 99 
L ND 39 28.40 102 
L ND 49 22.60 80 










1 1.3 2.9 48 
0.6 2 3.6 43 
2 3.4 5.8 39 
0.9  4 71 
1.1 3.7 5.5 34 
0.9 3.7 5.2 52 
1.4 3.8 6.1 40 
3.9 3.7 5 69 
0.4 2.3 3.9 41 
1 4.9 6.9 48 
0.7 1.7 3.6 49 
0.6 3.6 4.9  
1.1 4.4 6.2 4.4 
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1 3.1 4.9  
1.1 3.9 6 38 
0.9 3.1 4.6 37 
1.3 4.7 6.5 36 
1.4 3.6 5.3 41 
1 3 4.6 37 
1.5 3.7 5.7 38 










5.6 6.7   
5.2 6.7 1139.035 196.1148416 
4.8 5.5 721.27 124.1856061 
7.8 17.3 893.445 153.830062 
4.3 5.4 1068.2 183.9187328 
6 7.5 973.01 167.52927 
4.9 5.9 579.32 99.74517906 
7.6 8.2 850.8 146.4876033 
5 5.3 893.095 153.7698003 
5.6 7.9 1066.505 183.6268939 
5.7 8.2 1347.56 232.0179063 
5.6 6.6 1740.36 299.6487603 
5.8    
4.2 5.2 1160.125 199.7460399 
4.7 5.9 87.675 40 
4.6 5.7 561.845 189 
4.5 4.8 261.13 62.3 
5 5.3 375.42 64.6 
4.6 5.5 363.32 62.6 
4.7 5.9 240.46 41.4 






insulin 2 days after RYGB 
(pmol/L)  
HOMA-IR 2 days after 
RYGB 
 1.2   
45.32431895 3.3 118.612259 1033.849972 
26.49292929 0.9 140.6043388 776.0460015 
53.32775482 6.1 114.6969697 784.1707537 
35.14891338 1.6   
44.67447199 1.2 182.0532025 1355.521783 
21.72228344 2 100.1153581 443.8233033 
49.48025712 1.4 131.0347796 853.109814 
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34.17106673 2.6   
45.7026936 2.2 227.0377066 1852.899061 
58.77786961 2.5 178.3384986 1839.010003 
74.57924702 1.5 177.1935262 2359.814242 
    
37.28592746 1.9 241.5693871 2144.556819 
8.4 2.2   
38.6 1.3   
12.5 1   
14.4 0.92   
12.8 1.3   
8.6 1   
    
 






Waist follow up 
(cm) 
    
8 128.1 31.4 129 
7 112.5 31.5  
7 87.9 28.4 100 
    
6 115.2 34.8 119 
5 112 32 112 
7 98.8 31.9 118 
    
9 96.2 30 108 
5 127.8 35.4 122 
    
    
    
    
    
    
    
    
    
    
 
Table 12. Human Subject Information. This table displays relevant information about the human 






Table 13. Pyrosequencing Primers 
Runx1 Long 5' TTGAGTTTGTTAAATTTAGGGGTAAGT 
Runx1 Long 3' TTCAAACAACATTTTTAAATCATTTC 
Runx1 Nested 5' TTGAGTTTGTTAAATTTAGGGGTAAGT 











Pscdbp Long 5' TTTTTTAGGGAAAAGAATTTTTTTT 
Pscdbp Long 3' ATCTCAAACCACAACAATCACATAA 
Pscdbp Nested 5' GGTATTATTTTTAGTAGAGGTTAGGTAAA 








Stap1 Long 5' TTTTATAATAATTGAAGGAGGGAAAGT 
Stap1 Long 3' AAAAACAATATAACCCAAACAAAAAC 
Stap1 Nested 5' TTTTATAATAATTGAAGGAGGGAAAGT 








Pck1 Long 5' TGGTAAAGGTTTTGTTGTTTAAGTGT 
Pck1 Long 3' ATTCTCTAACCATCCCAAAATAAAC 
Pck1 Nested 5' TTTTTAGATATTTGGGTATTTAAGA 
Pck1 Nested 3' /5Biosg/ACTATAAACTTTATTCTAACAAAACAATAC 
Pck1 Sequencing 2 GTTTGATGTATATTTTTTTG 
Pck1 Sequencing 3 TTTAGAGTAGGGGTTAGTAT 
  
Dguok Long 5' AGTTGTATAATTTATTGTGGGTTGG 
Dguok Long 3' TCCTTTAAAACTTCCTCAAACATTT 
Dguok Nested 5' AGTTATGGAGGGTTAATTTGTGTTT 













Kcnj11 Long 5' AGAGTTTAGGTTATAGGTGGGAGGT 
Kcnj11 Long 3' AAAATATCCTACCAACCAAAAAAAA 
Kcnj11 Nested 5' TTTAGGTTATGTTTAAGGGTTTTGG 











Zfhnx2 Long 5' TTTTGAGGGTTTAGTGGTAGTTTGT 
Zfhnx2 Long 3' CAAATTCAATAAAAACACAAATTAAAAAA 
Zfhnx2 Nested 5' AGGGTTTAGTGGTAGTTTGTTAGGTTAT 








Slc38a4 Long 5' GGAGTTTTTATTAGGAGAGGGTGTAG 
Slc38a4 Long 3' ATAAACCAAAATAACCTCCAACTCA 
Slc38a4 Nested 5' TATTTTGATGGTGTTAGAGATGAATTT 











Chpt1 Outer F GGGAGTTTAGAATAGTGATTGGTTG 
Chpt1 Outer R TCCCTTCCTTAAATAACCTTCCTAC 
Chpt1 Inner F GGGAAGATTTTTAAATAGAGAGGATGT 
Chpt1 Outer R /5BiosG/TACCCTAAAAACTAAACCCCAAAAC 
Chpt1 Seq2 GATATTTAATATAATATTTATTT 
Chpt1 Seq3 ATTGAGTTTTAGGTTAGTTTTA 
Chpt1 Seq4 TTGGGGGAATTAATTTAAGT 
  
Liph Outer F ATAGTTTAGGAGGAAAGTTGGTGTT 
120 
 
Liph Outer R AAAAACTTCCAAAACATAAAAAAAA 
Liph Inner F AAGGGATTTAAGGGATTTTTAAATTT 
Liph Inner R /5BiosG/CAACTCCCTACAACAAAACACTTT 
Liph Seq1 GGTAGTTTGGTTTATTT 
Liph Seq2 GATTATTTAGATGTTTGT 
Liph Seq3 GTGGTATGATAGGTAGTAG 
  
Fasn Outer F GGGTTTTAAGAGGTTGTTGGTTAAT 
Fasn Outer R AACCCTAAACAAAACACAATTTCAC 
Fasn Inner F TAGTTTGTTTTGGGATAGGTTGTG 
Fasn Inner R /5BiosG/AATATACCCCCAAAAATAAAAAACC 
Fasn Seq1 GAATATAAAGGTTAAGTGTTTA 
Fasn Seq2 AGAGTTTGGGTAGTTAGATAG 
Fasn Seq3 AGGGTTTTTATTTTTATTAAG 
Fasn Seq4 GTTAATTAAATTTTTTAATTTG 
  
Axin2 Outer F GATTTTTAAGGAGGGGATTTTGTAG 
Axin2 Outer R CTATCCCACATCACCAATCTAAACT 
Axin2 Inner F TTTTTTTATTTTATGTGGTGTTTGT 
Axin2 Inner R /5BiosG/ACTAAAACTATCCCTACCTATTCCTC 
Axin2 Seq1 TTTTATTTTATGTGGTGTT 
Axin2 Seq2 TAATTGTTTTTGTTTTTTG 
Axin2 Seq3 GAATTTTAGAGTGAGGATTTG 
  
Scd1 Outer F AGAAGGTTTGGGGTAATATAGAAGTTT 
Scd1 Outer R AAATCCCCTCTCCTTAAAACATAAC 
Scd1 Inner F TGGGAAATTTTTTGATAGTT 
Scd1 Inner R /5Biosg/AATTCTACTAAATCCTCAAAAAAACTAAAC 
Scd1 Seq1 TTTGGGTTATATATGTGTTA 
Scd1 Seq2 GTTTTTGTATTTGTGAGGG 
  
Scd1 Outer F AAGGGAGGTTTTTGTTATTTATTTA 
Scd1 Outer R ACCTTCCTTATAACCATCAATTCC 
Scd1 Inner F TGTTTTTTAGTAAGTGAGAAGAGATGGT 
Scd1 Inner R /5Biosg/AACCAAATTTAAACCCAACCTAAAC 
Scd1 Seq1 GTGGTTTAGAAAGAAGAGTTTTGT 
  
Fermt2 Outer F TGTGGTAAGGTTTATTTTTTAGAGG 
Fermt2 Outer R AAACAAACTTTTATCTCCCCTTTTAC 
Fermt2 Inner F ATAATAGAGGATAGAAATAAAAGAATGAAA 
Fermt2 Inner R /5Biosg/CCTTCAAATTATATAAATTTCAAATAATAA 




Atp6v0a1 Outer F TTTTGGAATTAGTTTAAAAGGGTTG 
Atp6v0a1 Outer R AACAAAAAACAAAACAAAACCAAAT 
Atp6v0a1 Inner F ATTTTTAAGTAGGGATTTTTTTGTGAG 
Atp6v0a1 Inner R /5Biosg/TCATCCTAATACCTTCAAACTACTCTC 
Atp6v0a1 Seq1 GATAAGATTTTAATGTATTTAAGTT 
  
Arhgap29 Outer F TATGGATTTTGGGATTTTTGATTAT 
Arhgap29 Outer R TACAACAACCTAACCAACAAAAAAA 
Arhgap29 Inner F TTTTAATTTTGAATTTAGAGGAAATTTAGT 
Arhgap29 Inner R /5Biosg/AAAATATTTAATAAATTTCTATTCCCCC 
Arhgap29 Seq1 GTTATTTGTATTTTTGTTAAATT 
Arhgap29 Seq2 TTGTAAAGTGTTTGTTGATAA 
Arhgap29 Seq3 ATTAGATATTTTTGTTATAATTT 
  
Masp1 Outer F TATGTGTATTTATATTTGGGATTTTTTTAG 
Masp1 Outer R AATAAAACTCTTCTAACCCCTAAACTC 
Masp1 Inner F GAAGTTTGTGTTGTTTGTATTTTTG 
Masp1 Inner R /5Biosg/TCTATATTTACTTAAAACATACCCTC 
Masp1 Seq1 GGTTTTGGTGTTTTTGGAGTGGGAGA 
Masp1 Seq2 GTTATGTAGTAGGTGAAATGAGTT 
  
Elovl5 Outer F TTGTTGTATAGGTTTGTAGTTTAGGAGTAA 
Elovl5 Outer R TCAAAAACCCAATTAAATCAATATTC 
Elovl5 Inner F AAAATTGTTTAAGAGTATATTTTTTAAAAA 
Elovl5 Inner R /5Biosg/AACATCCAACATTAATTTCCTTACC 
Elovl5 Seq1 ATTTTTATTGTTAAGTTATATATGATT 
Elovl5 Seq2 TAGAGGTTTTTTAAAGAATGTG 
Elovl5 Seq3 ATTTTGTAAATTAAATTAGATGG 
  
Tmem140 Outer F TATAGAATGATGTTTATAAAGTGGGATATA 
Tmem140 Outer R AATTAAAAACCCCATAACACTCTTCT 
Tmem140 Inner F GGGATATAAATATATATATTTATGTAATTT 
Tmem140 Inner R /5Biosg/AACCAATATTTCCTTCAAAAAACAA 
Tmem140 Seq1 AGAAGTGTGTTGTTTAGAGTGGT 
 






Table S11. qPCR primers 
Tnks1bp1 F CCCAGGACCCTCACTCCAT 
Tnks1bp1 R TCCCAAACTCCCAGTCTTGAA 
Fbxw8 F GCCAGGTTGCCTTTGGAGT 
Fbxw8 R TCCCGGATGTTGACACAGGTA 
Sorbs1 F CCCCGTCTGAGGTAATAGTTGT 
Sorbs1 R GAGCAGTCTCCAGGAGTATAGTC 
Vps13c F GAAGCTAAAGTAAAAGCCCACGA 
Vps13c R ACACATCAGAGGTGTTGACAATG 
Tcf7l2 F AACGAACACAGCGAATGTTTCC 
Tcf7l2 R CACCTTGTATGTAGCGAACGC 
Pcx F CTGAAGTTCCAAACAGTTCGAGG 
Pcx R CGCACGAAACACTCGGATG 
Tnfsf8 F GCACAAGTCGCAGCTACTTCT 
Tnfsf8 R GGAGTGGAGTCCTTTTTCTGG 
Etaa1 F GGTGGCACGGGAATGAGTC 
Etaa1 R GATTTGTACTGGCGTCTCCTTT 
Pck1 F CTGCATAACGGTCTGGACTTC 
Pck1 R CAGCAACTGCCCGTACTCC 
Rgs3 F GCTTCCTGTAGGACAAGACCT 
Rgs3 R GGCTTTGAGGGGGCTTAGG 
Stau1 F GGACCCTCACTCTCGGATG 
Stau1 R TTCTGGCAGGGGTTCACTCT 
As3mt F GGGAATGTACTGAAGACATCTGC 
As3mt R CCACAGCCATAATACCTCGAACT 
Akt2 F ACGTGGTGAATACATCAAGACC 
Akt2 R GCTACAGAGAAATTGTTCAGGGG 
Tnfaip8l2 F TCAGCTCAAAGAGTCTGGCAC 
Tnfaip8l2 R GGTAAAGCTCGTCTAGCACCTC 
 










Total Subjects  524 459 346 
Sex     
 Male 364 324 256 
 Female 160 135 90 
Age     
 Min 46 46 4 
 1st Quartile 64.75 64 64 
 Median 71 71 71 
 3rd Quartile 77 77 77 
 Max 90 88 86 
BMI     
 Min 16.85 16.85 18.42 
 1st Quartile 25.58 25.62 25.78 
 Median 28.18 28.23 28.26 
 3rd Quartile 31.36 31.42 31.6 
 Max 47.26 47.26 45.97 
Education     
 Grade 12, GED, or less 184 165 123 
 Post-high school education, no 
bachelor's 
161 141 100 
 Bachelor's or graduate school degree 170 146 116 
 Prefer not to answer 9 7 7 
Smoking     
 Never smoked 129 114 87 
 Former smoker 365 319 241 
 Current smoker 30 26 18 
Alcohol     
 No drinking 142 124 86 
 Less than 7 drinks per week 238 215 167 
 Greater than six drinks per week 142 118 92 
Diabetes     
 No 413 370 275 
 Yes 103 82 65 
 Maybe 5 4 3 
 





 FHS CAD cohort post-QC 
removals 
 Paired cohort (only paired 
samples) 
 
Phenotype Cases Controls p-value Cases Controls p-
value 
% Male 74.90% 67.10% 0.4933 74% 74% 1 










Education     5.3 0.0095 
Grade 12, GED, or 
less 
83 82  69 54  
Less than 
Bachelor's 
61 80 0.0778 50 50 0.0449 
Bachelor's or 
graduate degree 
59 87  50 66  
Smoking       
Never 34 80  28 59  




Current 20 6  15 3  
Alcohol       
None 58 66  47 39  
Low 90 125 0.632 80 87 0.549 
High 59 59  46 46  
High Blood Sugar 
or Diabetes 
      
Yes 48 34 0.19 41 24 0.307 
No 156 214  129 146  
 
Table 16. Bivariate statistics for the Framingham Heart Study coronary heart disease cohort. Here we 
present population data for the final cohorts utilized in the CHD analysis, partitioning into cases and 
controls and analyzed to determine possible confounding effects of sensitivity variables versus the main 
case-control analysis. Binary variables were tested with Student’s T-test. Ordinal variables were tested 






Probe beta pval Gene region distance 
cg24145146 -0.00755 7.56E-
07 
ZNF624 downstream 40208 
cg03636183 -0.02817 2.97E-
06 
BTG2 inside 1263 
cg03746015 -0.02237 4.71E-
06 
RGS9 upstream 14052 
cg08417719 -0.00657 4.93E-
06 
CALCOCO1 promoter 100 
cg15803765 0.00278 8.62E-
06 
CPD promoter 478 
cg03725309 -0.00964 9.71E-
06 
LINC00635 NA 0 
cg21566642 -0.01942 1.08E-
05 
FBXL20 promoter 948 
cg02741440 0.021064 1.45E-
05 
NMNAT3 inside 50151 
cg08899667 0.015847 1.57E-
05 
UBE2G1 downstream 99148 
cg18597709 0.011132 1.79E-
05 
SPRY4 promoter 457 
cg10589385 0.041443 2.04E-
05 
ARRB2 inside 7445 
cg19337279 0.017077 2.34E-
05 
MAN1C1 upstream 7282 
cg00828616 -0.00466 2.63E-
05 
STAC3 inside 318 
cg13078421 0.015352 2.80E-
05 
GUCY1B2 NA 0 
cg05575921 -0.03299 2.86E-
05 
SYNGR3 inside 249 
cg24878115 0.007848 2.99E-
05 
INS-IGF2 NA 0 
cg17750139 -0.00234 3.11E-
05 
ZMYND15 inside 5639 
cg23478225 -0.01344 3.90E-
05 
ARFGEF1 inside 88518 
cg12347346 -0.02176 3.94E-
05 
TREML5P NA 0 
cg14172849 0.011574 4.19E-
05 
SPON1 inside 360 
cg06756624 -0.00604 4.20E-
05 
MC1R promoter 2019 
cg05951221 -0.02419 4.28E-
05 





PITX2 downstream 11575 
cg27388345 -0.00367 4.61E-
05 
AC007246.3 NA 0 
cg12798040 0.013638 4.63E-
05 
GNG7 inside 155902 
cg26575389 -0.01217 5.07E-
05 
ZNF175 promoter 61 
cg11798876 -0.00634 5.32E-
05 
TANC2 inside 32270 
cg26314512 -0.01269 5.49E-
05 
PDE4B inside 225 
cg21230425 -0.01775 5.52E-
05 
CHEK2P2 NA 0 
cg04135110 0.01433 5.58E-
05 
KNDC1 inside 2013 
cg04516896 -0.00674 5.65E-
05 
UBE2E2 inside 638 
cg01940273 -0.02176 5.95E-
05 
PRKCZ inside 1192 
cg16717549 0.027613 6.22E-
05 
TCP11 inside 1126 
cg04148762 0.002051 6.27E-
05 
YEATS2 promoter 173 
cg16526137 -0.00331 6.80E-
05 
TBR1 inside 1062 
cg14601444 0.015836 7.33E-
05 
POT1 NA 0 
cg13126206 -0.00882 7.76E-
05 
LINC00937 NA 0 
cg22382836 0.018655 7.93E-
05 
LOC100294145 NA 0 
cg10673265 -0.00548 8.10E-
05 
FAM184B inside 76 
cg25512107 -0.00491 8.26E-
05 
CDKN1C promoter 342 
cg10752406 -0.00692 8.41E-
05 
TCERG1L NA 0 
cg25745600 -0.01096 8.59E-
05 
BPTF promoter 93 
cg09309711 0.006565 9.10E-
05 
GAK inside 78939 
cg23661483 0.011592 9.27E-
05 
RDH8 inside 8788 
cg26507427 0.016834 9.55E-
05 
CHRND inside 395 






FAM46D inside 29 
cg25721516 -0.00789 9.78E-
05 
PEBP1 promoter 125 
cg10209902 -0.00237 9.91E-
05 
PXDN inside 66471 
 
Table 17. Top results of Framingham Heart Study coronary heart disease epigenome-wide association 
study. Here we present the results of the primary model utilized to examine CHD. Probe represents the 
probe on the Illumina Infinium 450k BeadChip array and the corresponding CG. Beta represents the 
determined correlation coefficient between methylation and CHD status. p-value is the corresponding p-
value for that coefficient. Gene is the nearest gene to that probe, and the region and distance columns 
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